annual report living goals living n n v n living c r e living r e p n b l living n e p e n e n c e value innovationcontent company p product portfolio p shareholders perspective branded prescription key aspects medicines corporate bodies respiratory diseases highlights medicine cardiovascular diseases living innovation metabolic diseases living care oncology living responsibility diseases central living independence nervous system infectious diseases consumer health care cough cold group management p sore throat report pain gastrointestinal diseases information vitamins supplements group companies leg vein health report economic position urological diseases report postbalance sheet date events animal health risk report food producing animals report expected swine developments food producing animals poultry food producing animals consolidated p financial statements cattle companion animals overview major horse consolidated companies companion animals consolidated balance sheet small animals consolidated profit loss statement cash flow statement statement changes group equity notes consolidated financial statements auditors reportliving goals annual report living innovation p living care p living responsibility p living independence p tnetnocboehringer ingelheim group financial highlights amounts millions eur unless otherwise indicated change net sales region europe americas asia australia africa business prescription medicines consumer health care animal health biopharmaceuticals industrial customers sales research development personnel costs average number employees operating income operating income net sales income taxes income taxes net sales shareholders equity return shareholders equity cash flow investments tangible assets depreciation tangible assets top products prescription medicines top products consumer health care net sales millions eur change net sales millions eur change spiriva buscopan micardis dulcolax pradaxa mucosolvan combivent pharmaton v company boehringer ingelheim group one worlds lead ing pharmaceutical companies headquartered ingelheim germany boehringer ingelheim operates globally af filiates total employees focus familyowned company founded researching developing manufacturing marketing new medications high therapeutic value human veterinary medicine taking social responsibility important element corporate culture boehringer ingelheim includes worldwide involvement social projects initiative making health caring employees respect equal opportunities reconciling career family form foundation mutual cooperation everything company focuses environmental protection sustainability shareholders perspective shareholders perspective christian boehringer chairman shareholders committee shareholder family boehringer ingelheim determined path company taken given continued support almost years create sound financial structure committed providing longterm strategy thereby offer prerequisites sta bility profitability sustainable growth founder com pany albert boehringer laid foundations w e therefore dedicated chapter living independence annual report independence paramount objective reason firmly anchored understanding boehringer ingelheim company also stands innovation care responsibility included excellent examples annual report research scientist boehringer ingelheim annual report business year shareholders perspective research institute molecular pathology vienna sup ported boehringer ingelheim patient australia employee italy actively involved boehringer ingelheims social projects values mean us shareholders innovation driver growth company right start true vision value innovation began pro duction tartaric lactic acid followed first medicines research department set boehringer ingel heim one pioneers field biopharmaceuticals today pharmaceutical products portfolio various therapeutic areas respiratory diseases cardiovascular diseases metabolism oncology disorders central nervous system immunology next two years alone planning launch twelve new medicines treatment widely differing indications successes would unthinkable without intense research development many years also placed high value collaboration external partners fields science industry frequently relatively small biotechnology firms thus provide platform transfer knowledge expertise parties benefit examples include collaboration research institute molecular pathology imp vienna scientific collaboration university dresden collaboration firms circuit thera peutics california guiding principle research development work meet medical needs patients goal supply medicines help provide new effective efficient therapy options mean speak caring ethical company thereby focus medicines high sales potential also carry r esearch medicines treatment rare diseases example possible compound nintedanib may used treatment idiopathic pulmonary fibrosis aml rare form leukaemia currently testing compound volasertib shareholders perspective fundamental aspect see assume responsibility people limited corporate activities boehringer ingelheim social responsibility commitment society many facets integral part corporate philoso phy since beginning example made compound nevirapine prevention hiv transmission mother child birth available free charge developing countries ten years also made possible generic manufacturers pro duce market nevirapine without demanding licence fees way helped ensure availability medicines combat hiv aids longer price issue making health initiative working nonprofit organisation ashoka promote sustainable health initiatives worldwide end making health supports social entrepreneurs healthcare field around globe searching new better ways improving health helping people obtain easier access medical solutions also live matter responsibility everyday work way deal company characterised mutual respect responsibility others individual contributes po sition creating value innovation accepting responsibility actions others true things going well also times difficult seen financial year ended easy year complaints made us food drug administration fda quality assurance processes ingelheim presented us major challenges members staff subsequently done exceptional job establishing prerequisites followup inspection shortest time however remain occupied revision optimisation quality systems years ahead boehringer ingelheim annual report business year key aspects would like thank members staff board managing directors course great commitment efforts company looking back last year also much report pleasing nature successfully entered therapeutic area oncology developed fields diabetes respiratory diseases new products also added animal health consumer health care overall created basis ensure continuing longterm success certain another challenging year however cer tainly look forward confidence future boehringer ingelheim well positioned master challenges together continue work successfully live goals thus attain supreme goal independence familyowned company signed christian boehringer chairman shareholders committee key aspects key aspects allan hillgrove joachim hasenmaier andreas barner hubertus von baumbach wolfgang baiker left right board managing directors look back previous financial year two different angles one hand seen local viewpoint grown albeit moderately com parison previous year increased result absolute terms profi tability distinctly despite forced absorb considerable negative currency effects hand easy year boehringer ingelheim reasons include complaints made quality assurance processes production facility ingelheim us food drug administration fda closing us facility bedford ohio fact growth weaker comparison previous years result increasingly difficult market environment europe example also usa japan view challenges year transition boehringer ingelheim boehringer ingelheim annual report business year decisive factor boehringer ingelheim entire workforce able face challenges successfully make necessary changes thus lay foundations positive development years ahead achievements research development research development large number achievements show par ticularly expanded product portfolio yet compound afatinib successfully entered field oncology addition diabetes second new therapeutic area boehringer ingelheim afatinib used targeted treatment lung cancer put us market name gilotrif launch also begun european union novel oncology compound nintedanib phase iii clinical trial shown first treatment lung cancer combination chemotherapy extend life patients adenocarcinoma initial treatment failed year field diabetes successfully completed key phase iii trials com pound empagliflozin submitted application international marketing authorisation expect receive initial authorisation market launch year also delighted success field respiratory diseases results phase iii trial involving patients chronic obstructive pulmonary disease copd shown olodaterol respimat addition current standard treatment exception longlasting beta agonists leads statistically sig nificant improvement lung function olodaterol approved use brand name striverdi respimat first time submissions medicines therapeutic areas currently schedule pharmaceutical research development however setbacks also possible final straight something experienced recently interferonfree combination hepatitis c compounds faldaprevir deleobuvir live expectations preliminary evaluation phase iii trial december showed reason decided terminate development deleobuvir expect receive initial approvals interferonbased programme faldaprevir towards end year examine activities field hepatitis c therapy depth also view convincing clinical data competi tors field key aspects research development secures future portfolio medicines thus future business success next two years alone planning introduce twelve new products eight indications diabetes copd asthma lung cancer idio pathic pulmonary fibrosis ipf rare form leukaemia aml addition treatment prevention deep vein thrombosis pulmonary embolism research development overall currently working projects last year expenditure projects million euros remained high level equivalent per cent net sales people employed research development boehringer ingelheim key growth driver pradaxa despite continuing difficult market environment achieved currency adjusted growth net sales lower singledigit range taking account negative currency effects results per cent decline net sales compared previous year growth driver proved oral anticoagulant pradaxa net sales rose per cent million euros net sales million euros spiriva treatment copd bestselling product previous year able increase operating income per cent million euros results improved return net sales per cent shows successful offsetting extraordinary factors negatively affected result implementing initiatives last year designed increase efficiency reduce costs included situation ben venue us production facility sterile injection solutions spite major efforts already undertaken return future compatible stable production would possible particu larly market environment changed considerably facility therefore closed end year extensive reorganisation production pro cesses ingelheim preparation followup inspection us food drug administration affected result market situation medicines changing rapidly worldwide remains impor tant us therefore continuously examine internal structures process decisive question always improve optimise way respond customers needs background restructured regional business operations revised strategies various therapeutic areas strengthened organisation boehringer ingelheim annual report business year market access innovative medicines increasingly difficult view ageing population health systems worldwide faced chal lenge continuously increasing costs therefore undergoing sustained change one hand increase demand innovative medicines long term also help relieve burden placed systems providing effective alternative therapies hand financial budgetary demands health systems increase short term immediate impact budgets pharmaceutical products therefore challenge industry short term long term presenting great opportunity striking example shortterm challenge germany new laws resulted substantial cuts pharmaceutical companies involved research thus becoming difficult bring medicines researched produced germany german market well reason take difficult decision offer trajenta medicine treatment diabetes germany added benefit medicine rejected would place medicine meantime approved countries german market price could justified although expect extensive clinical trials necessity take place approval given demonstrate distinct added benefit damage research company germany already done situation inconsistent economic importance boehringer ingelheim germany since growth boehringer ingelheims gross value added germany around three times high german economy whole data pub lished independent economic research institute wifor shows socalled health satellite account outlook continuing difficult market environment impact patent losses large number markets usual industry mean expect face chal lenges view situation expect net sales current fi nancial year level comparable achieved boehringer ingelheim launch new medicines intend introduce market year years ahead foreground activities key aspects priorities current financial year order lay foundation future growth continue focus efforts year intend drive growth forward business areas giving priority cost awareness efficiency ever needs customers guiding principle actions quality compliance words strict adherence established rules regulations given high priority production clear commitment transparency openness applies figures clinical tests trials company like boehringer ingelheim lives large degree expertise experience commitment entire workforce deserve special thanks particularly view challenging year continue place trust confidence active support loyalty together lay foundations year enable us put company back growth path signed signed andreas barner wolfgang baiker signed signed hubertus von baumbach joachim hasenmaier signed allan hillgrove boehringer ingelheim annual report business year corporate bodies corporate bodies shareholders committee board managing directors christian boehringer prof dr dr andreas barner chairman shareholders committee chairman board corporate board divisions human resources christoph boehringer research development medicine erich von baumbach jr dr wolfgang baiker isabel boehringer corporate board divisions operations dr mathias boehringer biopharmaceuticals hubertus von baumbach advisory board corporate board division finance prof dr michael hoffmannbecking prof hc dr wolfram carius corporate board divisions operations attorney law dsseldorf biopharmaceuticals chairman advisory board dr joachim hasenmaier egbert appel corporate board divisions animal health trustee martin hilti family trust consumer health care president hilti foundation chairman advisory board allan hillgrove corporate board division kurt beck pharma marketing sales former ministerpresident dr andreas kreimeyer member board executive directors research executive director basf se jan rinnert chairman board management chief financial officer heraeus holding gmbh republic austria highlights medicine highlights medicine new products market new substances submitted registration new study results published one successful years ever continue individual markets pradaxa boehringer ingelheim terms launches submis treatment dvt pe striverdi respimat sions new biological chemical entities company boehringer ingelheim also submitted registration individual markets launched giotrif indica documentation europe tiotropium asthma tion nonsmall cell lung cancer nsclc pradaxa diabetes alliance boehringer ingelheim treatment prevention deep vein thrombosis eli lilly company submissions empagliflozin dvt pulmonary embolism pe well received adults type diabetes new insulin european approval striverdi olodaterol respimat glargine product type type diabetes chronic obstructive pulmonary disease copd filed boehringer ingelheim entering new therapeutic company thus continues successful path renewing area faldaprevir hepatitis c late expanding product portfolio managed commence registration process novel compound well boehringer ingelheims second oncology product nintedanib nsclc registration process overview important boehringer ingelheim authorities started additional registration processes clinical studies metabolism linagliptin trajenta linagliptin carmelina trial investigating effect resulting data highly relevant receiving placebo adverse events seen linagliptin versus standard care cardio treatment selection last patient recruit linagliptin occurred comparable vascular renal microvascular events ment carolina accomplished frequency placebo study group consists adults november significant difference compared placebo type diabetes risk cardiovascular terms hypoglycaemia patients renal events patient enrolment started received concomitant treatments treatment elderly type diabetes patients july known increase risk hypoglycae complex challenging data mia insulin phase iii study published lancet ongoing carolina study august showed blood glucose eventdriven headtohead cardiovascular levels elderly people type diabetes outcomes trial comparing dpp inhibitor following week treatment linaglip linagliptin sulfonylurea glimepiride tin dropped significantly compared boehringer ingelheim annual report metabolism empagliflozin end first half international diabetes congresses number pivotal studies investi addition enrolment trials pro gational agent empagliflozin finally gramme completed july completed phase iii clinical trials pro empareg outcome trial eventdriven gramme empareg empagliflozin cardiovascular endpoint study evaluating member sodium glucose cotrans effect empagliflozin versus standard treat porter sglt inhibitor class drugs ment people type diabetes programme focused type diabetes high cardiovascular risk boehringer enrolled patients com ingelheim confident large data set empagliflozin prised ten multinational clinical convince authorities registration trials key study data released various process cardiovascularvascular diseases pradaxa clinical trials boehringer ingelheim expanded clinical development programme pradaxa dabigatran etexilate thus pinning continued leadership commit ment innovative solutions benefit patients physicians worldwide dabigatran etexilate remedy resonate future antidote recover commitment development key findings clinical trials addition boehringer ingelheim con boehringer ingelheim permanently commit contributed regulatory submissions tinue gather realworld clinical data ted patient safety context com pradaxa treatment acute patients nonvalvular atrial fibrillation pany developing specific highly selec prevention dvt pe well subse undertake research use tive humanised antibody fragment provide quent secondary prevention results pradaxa new cardiovascular patient popu physicians rare emergencies addi remedy recover resonate lations end company tional option halt anticoagulant effect published prestigious journals announced two new phase iii studies pradaxa new england journal medicine planned respect esus research circulation conducted well safely initial results studies healthy test pradaxa prevent strokes persons phase clinical studies show patients whose initial stroke caused results demonstrate efficacy favoura potential antibody fragment fab blood clot unknown origin redual pci ble safety profile pradaxa impor specific antidote halt anticoagulant investigate well safely pradaxa tant areas still unmet medical need effect dabigatran immediately completely prevent blood clots patients atrial lasting basis fibrillation coronary stent implant due narrowing blood vessels highlights medicine oncology hepatitis c virus afatinib faldaprevir giotrif afatinib june boehringer ingelheim pre nonsmall cell lung cancer nsclc sented data luxlung phase iii positive egfr erbb mutation status trial showed per cent demonstrated treatment patients receiving giotrif afatinib giotrif patients type faldaprevir tumour progressionfree one year lung cancer leads significant delay treatment compared per cent tumour progression improvements patients chemotherapy diseaserelated symptoms like short results presented ness breath cough chest pain well boehringer ingelheims startverso phase iii improved quality life new results confirmed findings programme investigated faldaprevir companys previous phase iii trial lux combination pegylated interferon lung compared afatinib different giotrif approved authorities ribavirin hepatitis c patients geno chemotherapy regimen pemetrexedcisplatin european union number addi type difficult genotype treat result giotrif superior com tional countries usa registered trial programme investigated treatment pared standard chemotherapies patients brand name gilotrif nave patients startverso treatment experienced patients startverso hiv coinfected patients startverso overall studies encompassed patients faldaprevir proved safe efficacious many patients infected genotype hepatitis including advanced liver disease per cent pre nintedanib viously untreated patients early treatment success achieved thereby enabling shorter treatment duration furthermore due oncedaily administration without dietary restrictions compound offers simpler convenient option current nintedanib standard treatment end company submitted results lumelung phase iii involved angiogenesis tumour growth faldaprevir registration food clinical trial show novel investiga importantly patients benefited addi drug administration fda european tional compound nintedanib first lung tional efficacy nintedanib without medicines agency ema authori cancer treatment combined impairing quality life ties worldwide chemotherapy extend survival beyond one year patient whose initial therapy basis results boehringer failed earlier patients firstline ingelheim submitted nintedanib euro therapy failed greater benefit pean medicines agency regulatory nintedanib provided compared control agencies second half group nintedanib oral triple angiokinase inhibitor targets three receptors crucially boehringer ingelheim annual report respiratory diseases tiotropium tiotropium spiriva respimat asthma spiriva handihaler least per cent asthma patients still tiotropium safety performance study spiriva handihaler suffer symptoms despite currently avail respimat tiospir global landmark trial survival advantage shown com able treatment options experience patients one pared control therapy tiospir asthma exacerbations attacks gratifying largest chronic obstructive pulmonary trial population selected broad inclusion new data tiotropium asthma prove disease copd trials ever conducted criteria representative typical copd tiotropium respimat effective sympto compared spiriva respimat two doses patients presenting daytoday practice matic asthma patients irrespective spiriva handihaler g results included patients copd disease allergic status age smoking habits published ers congress sep severities comprehensive use con bronchodilator response tiotropium tember simultaneously new comitant copd medications patients administered daily via respimat signi england journal medicine medical history cardiac disorders ficantly improved lung function data form basis submis sion approval spiriva respimat furthermore similar impact survival usa primotinaasthma studies two demonstrated spiriva respimat doubleblind parallelgroup trials including spiriva handihaler tiospir trial asthma patients still showed symptoms important earlier uplift despite treatment least inhaled corti costeroids icslongacting betaagonists laba total patients ran domised additional therapy tiotro pium respimat placebo weeks tiotropium reduced asthma exacerbations olodaterol patients retained symptoms despite treatment least ics laba irre spective allergic status data mezzotinaasthma phase iii striverdi respimat twin studies presented first time european respiratory society ers congress confirmed statistically signifi cant clinically relevant improvement results phase iii study presented lung function improvements hours asthma control oncedaily tiotropium medical congress barcelona spain combination usual therapy medi provides patients continue show september showed cine rapidly takes effect within five minutes symptoms despite treatment ics patients olodaterol respimat first dose lung function improvement addition usual care provides statistically oncedaily olodaterol respimat results registration process tiotropium significant improvement lung function copd patients achieving meaningful asthma started eu second improvement quality life usual half olodaterol highly selective longacting care alone betaagonist laba boehringer ingelheims research pipeline oncedaily olodaterol received first registrations administered olodaterol respimat maintains brand name striverdi respimat follow name luisa cochella occupation group leader nose research institute molecular pathology imp year birth location vienna austria innovation means aring face un known going one gone luisa cochella colleagues involved worm identified cells takes vision course groundbreaking work scientists act molecular biologists involved also type persever research institute molecular pathology imp microrna research course luisa ance almost vienna carrying research determine wants first prepare comprehensive confused happens molecular level cells model microrna processes round stubbornness divide cancerous tumours develop worm role micrornas play development organism imp largely sponsored potential use oncology boehringer ingelheim carries basic work could eventually help development research completely independent basis new types medicine micrornas could used oncology biomarkers example buenos aires vienna detect tumours included medicines luisa typical representative leading inhibit growth tumours internationally renowned research institute important cell differentiation could born buenos aires argentina studied possibly used cultivate tissues trans usa dutch partner also plantation visions still far luisa molecular biologist moved vienna grateful boehringer ingelheim heads fivemember international imps sponsor also farsightedness team research scientists undertake basic research first place characterises truly innovative company imp conducting research work says biologist micrornas roundworm c elegans scien tists discovered short ribonucleic acid mole ensure information could cules micrornas consist practical use lost imp research scientists nucleotides present virtually hold regular meetings exchange views multicellular organisms years ago information boehringer ingelheim micrornas ensure example cells meet example joint symposium divide uncontrolled manner held year year topic many different cell types body develop micrornas medical applications says luisa fertilised egg proudly quite possible worms fluorescent sensory neuron help understand detail luisa exchanges drug developers come bright new genes switches individual micrornas ideas waits see worms change already isolated micrornas follow name luisa cochella occupation group leader nose research institute molecular pathology imp year birth living n n v n location vienna austria innovation means aring face un known going boehringer ingelheim carries research new diseases develops one gone luisa cochellan aenwd dherur cgosl laenagdu tehs earrae pinievsol viendn ovatiionn th eth weorremfo arned iisd evnittaifil efdo ri nt hweh ficuht ucreell tfh tehy e takes vision course groundbreaking work scientists act molecular biologists involved company means boehringer ingelheim relies research also type persever research institute molecular pathology imp microrna research course luisa development also places great emphasis collaboration ance almost vienna carrying research determine wants first prepare comprehensive confused happens wati tthhe e mxtoelercnualla pr laervtenl ewrsh en fcreolmls acadmeomdeicl oinf asltli tmuitcerso rannda bpiroocpehsasersm ina ctheeu rtoicuanld stubbornness divide cancecroomusp taunmioeusr tso esvtaelrotpu apnsd worm role micrornas play development organism imp largely sponsored potential use oncology boehringer ingelheim carries basic work could eventually help development research completely independent basis new types medicine micrornas could used oncology biomarkers example buenos aires vienna detect tumours included medicines luisa typical representative leading inhibit growth tumours internationally renowned research institute important cell differentiation could born buenos aires argentina studied possibly used cultivate tissues trans usa dutch partner also plantation visions still far luisa molecular biologist moved vienna grateful boehringer ingelheim heads fivemember international imps sponsor also farsightedness team research scientists undertake basic research first place characterises truly innovative company imp conducting research work says biologist micrornas roundworm c elegans scien tists discovered short ribonucleic acid mole ensure information could cules micrornas consist practical use lost imp research scientists nucleotides present virtually hold regular meetings exchange views multicellular organisms years ago information boehringer ingelheim micrornas ensure example cells meet example joint symposium divide uncontrolled manner held year year topic many different cell types body develop micrornas medical applications says luisa fertilised egg proudly quite possible worms fluorescent sensory neuron help understand detail luisa exchanges drug developers come bright new genes switches individual micrornas ideas waits see worms change already isolated micrornas follow nose luisa cochella colleagues involved worm identified cells groundbreaking work scientists act molecular biologists involved research institute molecular pathology imp microrna research course luisa vienna carrying research determine wants first prepare comprehensive happens molecular level cells model microrna processes round divide cancerous tumours develop worm role micrornas play development organism imp largely sponsored potential use oncology boehringer ingelheim carries basic work could eventually help development research completely independent basis new types medicine micrornas could used oncology biomarkers example buenos aires vienna detect tumours included medicines luisa typical representative leading inhibit growth tumours internationally renowned research institute important cell differentiation could born buenos aires argentina studied possibly used cultivate tissues trans usa dutch partner also plantation visions still far luisa molecular biologist moved vienna grateful boehringer ingelheim heads fivemember international imps sponsor also farsightedness team research scientists undertake basic research first place characterises truly innovative company imp conducting research work says biologist micrornas roundworm c elegans scien tists discovered short ribonucleic acid mole ensure information could cules micrornas consist practical use lost imp research scientists nucleotides present virtually hold regular meetings exchange views multicellular organisms years ago information boehringer ingelheim micrornas ensure example cells meet example joint symposium divide uncontrolled manner held year year topic many different cell types body develop micrornas medical applications says luisa fertilised egg proudly quite possible worms fluorescent sensory neuron help understand detail luisa exchanges drug developers come bright new genes switches individual micrornas ideas waits see worms change already isolated micrornas research scientists follow boehringer nose ingelheim drives innovation first cancer drug market usa autumn afatinib oncology boehringer ingelheim luisa cochella colleagues involved worm identified cells became first cancer drug boehringer ingelheims research centre vienna groundbreaking work scientists act molecular biologists involved boehringer ingelheim placed specialists carrying research new research institute molecular pathology imp microrna research course luisa market marketed cancer drugs least due close collaboration vienna carrying research determine wants first prepare comprehensive brand name gilotrif industrial partners scientists imp aca happens molecular level cells model microrna processes round targeted treatment lung demic institutions worldwide acquired wealth divide cancerous tumours develop worm cancer medication also regis unique expertise field small molecules bio role micrornas play development tered european union therapeutics compound volasertib developed organism imp largely sponsored potential use oncology already launched countries boehringer ingelheim currently undergoing clinical trials boehringer ingelheim carries basic work could eventually help development example germany based research work cell division carried research completely independent basis new types medicine micrornas could name giotrif addition imp could future used acute myeloid leukaemia diabetes oncology used oncology biomarkers example second new therapeutic area buenos aires vienna detect tumours included medicines boehringer ingelheim luisa typical representative leading inhibit growth tumours internationally renowned research institute important cell differentiation could born buenos aires argentina studied possibly used cultivate tissues trans usa dutch partner also plantation visions still far luisa molecular biologist moved vienna grateful boehringer ingelheim years heads fivemember international imps sponsor also farsightedness team research scientists undertake basic research first place investments rd basic research characterises truly innovative company boehringer ingelheim continues invest international repute imp conducting research work says biologist research research work since boehringer ingelheim micrornas roundworm c elegans scien carried collaboration external sponsored highly reputed research tists discovered short ribonucleic acid mole ensure information could partners develop innovative drugs institute molecular pathology imp cules micrornas consist practical use lost imp research scientists administration methods com vienna austria nucleotides present virtually hold regular meetings exchange views pany spent per cent total sales scientists carry independent multicellular organisms years ago information boehringer ingelheim rd various therapeutic areas research already resulted micrornas ensure example cells meet example joint symposium amounted billion euros approximately patents results divide uncontrolled manner held year year topic imps work repeatedly used many different cell types body develop micrornas medical applications says luisa basis research new medicines independent fertilised egg proudly quite possible boehringer ingelheim foundation addi worms fluorescent sensory neuron help tionally set institute molecular understand detail luisa exchanges drug developers come bright new biology imb mainz germany genes switches individual micrornas ideas foundation financing scientific waits see worms change billion euros work carried period already isolated micrornas ten years donation mil lion eurosname audrey walsh occupation pensioner voluntary secretary illawarra cancer carers year birth location wollongong australia caring means b eing involved assisting others make lifes journey better comfort care able impart fighting fit name audrey walsh occupation pensioner voluntary secretary illawarra cancer carers year birth living c r e location wollongong australia caring means b eing involved boehringer ingelheim strives every day help patients around globe assisting others make lifes journey audrey walsh tiso awcohmieavne tf haicsti ognoa tlh teh reet icroedm panyc diaenvse tloo ipnsc liundne opvraatdiavxea roung tsh feo prh dairsmeaacseeust iwcailt h better tertiary educator works tirelessly volunteer benefits scheme pbs provides australians high unmet therapeutic need boehringer ingelheim involved comfort care caring cancer patients home town affordable access wide range innova traditional therapeutic areas within scope research develop able impart wollongong kilometres south sydney tive medicines couldnt accept fact secretarmy oefn itll pawroajrerac tcsa insc earl scoa reenrste ar lioncga ln ewa ndtiisceoaagsuel aanretsa wsere included pbs list charity organisation organises funding pradaxa says audrey even also charge volunteer member one take consideration course ships addition works week pradaxa also case power oncology ward hospital wollongong ful medicines lead undesired side effects example massages patients feet chats makes tea visitors coping atrial fibrillation audreys efforts intended show others unexpected diagnosis atrial fibrillation coping atrial fibrillation australian dedicated life caring life hardly changed since atrial fibril others occasionally however needs help lation diagnosis thats precisely whats someone else case one sunday fantastic says means september audrey arrived dont go clinic checkups visit daughter north queensland time organise day suddenly felt unwell rushed emergency department towns ville hospital cardiologist examined audrey walsh still active ever continues audrey diagnosed atrial fibrillation work illawarra cancer carers meets friends easily lead formation blood visits art exhibitions sydney walks least four clots subsequently result stroke times week travels around world cardiologist prescribed audrey anticoagulant spends time family recently pradaxa boehringer ingelheim travelled turkey visited berlin travelled along rhine went london sooner returned home canada plans go new zealand soon raring go wrote letters pradaxa also thanks support prime minister minister health pbs list local member parliament urging politi fighting fit audrey walsh woman action retired cians include pradaxa pharmaceutical tertiary educator works tirelessly volunteer benefits scheme pbs provides australians caring cancer patients home town affordable access wide range innova wollongong kilometres south sydney tive medicines couldnt accept fact secretary illawarra cancer carers local anticoagulants included pbs list charity organisation organises funding pradaxa says audrey even also charge volunteer member one take consideration course ships addition works week pradaxa also case power oncology ward hospital wollongong ful medicines lead undesired side effects example massages patients feet chats makes tea visitors coping atrial fibrillation audreys efforts intended show others unexpected diagnosis atrial fibrillation coping atrial fibrillation australian dedicated life caring life hardly changed since atrial fibril others occasionally however needs help lation diagnosis thats precisely whats someone else case one sunday fantastic says means september audrey arrived dont go clinic checkups visit daughter north queensland time organise day suddenly felt unwell rushed emergency department towns ville hospital cardiologist examined audrey walsh still active ever continues audrey diagnosed atrial fibrillation work illawarra cancer carers meets friends easily lead formation blood visits art exhibitions sydney walks least four clots subsequently result stroke times week travels around world cardiologist prescribed audrey anticoagulant spends time family recently pradaxa boehringer ingelheim travelled turkey visited berlin travelled along rhine went london sooner returned home canada plans go new zealand soon raring go wrote letters pradaxa also thanks support prime minister minister health pbs list local member parliament urging politifighting fit boehringer ingelheim patient experience cares health micardis micardis medicine used treat high blood pressure market years successful doctors accumulated total mil lion years experience patients successful product approved use countries worldwide currently marketed countries micardis million years family also includes micardisplus twynsta combination products audrey walsh woman action retired cians include pradaxa pharmaceutical tertiary educator works tirelessly volunteer benefits scheme pbs provides australians caring cancer patients home town affordable access wide range innova wollongong kilometres south sydney tive medicines couldnt accept fact secretary illawarra cancer carers local anticoagulants included pbs list charity organisation organises funding pradaxa says audrey even first european approval also charge volunteer member one take consideration course regular health checks overs striverdi respimat ships addition works week pradaxa also case power boehringer ingelheim takes care employees health part uk denmark iceland oncology ward hospital wollongong ful medicines lead undesired side effects german preventive health programme fit life fit first european countries example massages patients feet job company employees germany take part receive approval medicine chats makes tea visitors coping atrial fibrillation regular multistage health check aim purpose pre striverdi respimat new audreys efforts intended show others vention programme identify individual risk factors early medicine approved unexpected diagnosis atrial fibrillation coping atrial fibrillation stage together employees find deal countries date largescale australian dedicated life caring life hardly changed since atrial fibril service part corporate health management sys clinical trial programme involving others occasionally however needs help lation diagnosis thats precisely whats tem company received national corporate patients boehringer someone else case one sunday fantastic says means health award third time ingelheim demonstrated effectiveness medicine september audrey arrived dont go clinic checkups treating chronic obstructive visit daughter north queensland time organise day pulmonary disease copd suddenly felt unwell years rushed emergency department towns ville hospital cardiologist examined audrey walsh still active ever continues audrey diagnosed atrial fibrillation work illawarra cancer carers meets friends easily lead formation blood visits art exhibitions sydney walks least four clots subsequently result stroke times week travels around world cardiologist prescribed audrey anticoagulant spends time family recently pradaxa boehringer ingelheim travelled turkey visited berlin travelled along rhine went london sooner returned home canada plans go new zealand soon raring go wrote letters pradaxa also thanks support top products prime minister minister health pbs list boehringer ingelheims three successful pre local member parliament urging politi scription drugs spiriva treatment copd billion euros angiotensin receptor blocker micardis treatment high blood pressure anticoagulant pradaxa together generated net sales around billion eurosanything smile daniele de cillis office little reason laugh boehringer ingelheim boehringer ingelheim subsidiary milan six given support needed months superiors supported mained fully employed boehringer ingelheim boehringer ingelheim continued receive salary says convinced actively involved social time ive opportunity enterprise enriches lives employees dedicate something completely different enhances professional skills daniele adds head sales training spent six months work ing dynamo academy social enterprise involvement charity work way part dynamo camp one largest restricted break work dynamo academy charity organisations italy six years spending free time hospital clown putting costume recreation therapy camp heart tus wig perform silly tricks seriously ill cany children serious chronic illnesses children daniele even uses holidays enter take oneweek holiday without tain give children little happiness name daniele de cillis parents free charge back take away sadness little says occupation training manager daytoday life bring daniele reward hundredfold greater boehringer ingelheim memories beautiful holiday also idea normal life possible says daniele dedicated making health year birth first foremost however manager runs location milan italy dynamo academy generates money camp making health projects italy part able ensure camp initiative launched boehringer ingelheim responsibility means run increasingly sustainable manner nonprofit organisation ashoka making c hallenging paradigm money necessary among things health supports work social entre profit social need generated dynamo academy training preneurs healthcare field worldwide coexist centre annexed camp offers corporate team activities example danieles job daniele invests around quarter work revamp academys existing range seminars boehringer ingelheim projects boehringer ingelheim company actively daniele de cillis enthusiastic time supports social responsibility says spent academy camp expe knows something pre rienced much joy happiness zest scribed part corporate culture life young people first sight anything smile living r e p n b l taking responsibility others firmly anchored boehringer ingelheims corporate culture company years maintained commitment employees neighbours society environment based boehringer ingelheims four corporate values respect trust empathy daniele de cillis office little reason laugh boehringer ingelheim boehringer ingaenldhe pimas ssuibosnidiary milan six given support needed months superiors supported mained fully employed boehringer ingelheim boehringer ingelheim continued receive salary says convinced actively involved social time ive opportunity enterprise enriches lives employees dedicate something completely different enhances professional skills daniele adds head sales training spent six months work ing dynamo academy social enterprise involvement charity work way part dynamo camp one largest restricted break work dynamo academy charity organisations italy six years spending free time hospital clown putting costume recreation therapy camp heart tus wig perform silly tricks seriously ill cany children serious chronic illnesses children daniele even uses holidays enter take oneweek holiday without tain give children little happiness name daniele de cillis parents free charge back take away sadness little says occupation training manager daytoday life bring daniele reward hundredfold greater boehringer ingelheim memories beautiful holiday also idea normal life possible says daniele dedicated making health year birth first foremost however manager runs location milan italy dynamo academy generates money camp making health projects italy part able ensure camp initiative launched boehringer ingelheim responsibility means run increasingly sustainable manner nonprofit organisation ashoka making c hallenging paradigm money necessary among things health supports work social entre profit social need generated dynamo academy training preneurs healthcare field worldwide coexist centre annexed camp offers corporate team activities example danieles job daniele invests around quarter work revamp academys existing range seminars boehringer ingelheim projects boehringer ingelheim company actively daniele de cillis enthusiastic time supports social responsibility says spent academy camp expe knows something pre rienced much joy happiness zest scribed part corporate culture life young people first sight anything smile daniele de cillis office little reason laugh boehringer ingelheim boehringer ingelheim subsidiary milan six given support needed months superiors supported mained fully employed boehringer ingelheim boehringer ingelheim continued receive salary says convinced actively involved social time ive opportunity enterprise enriches lives employees dedicate something completely different enhances professional skills daniele adds head sales training spent six months work ing dynamo academy social enterprise involvement charity work way part dynamo camp one largest restricted break work dynamo academy charity organisations italy six years spending free time hospital clown putting costume recreation therapy camp heart tus wig perform silly tricks seriously ill cany children serious chronic illnesses children daniele even uses holidays enter take oneweek holiday without tain give children little happiness parents free charge back take away sadness little says daytoday life bring daniele reward hundredfold greater memories beautiful holiday also idea normal life possible says daniele dedicated making health first foremost however manager runs dynamo academy generates money camp making health projects italy part able ensure camp initiative launched boehringer ingelheim run increasingly sustainable manner nonprofit organisation ashoka making money necessary among things health supports work social entre generated dynamo academy training preneurs healthcare field worldwide centre annexed camp offers corporate team activities example danieles job daniele invests around quarter work revamp academys existing range seminars boehringer ingelheim projects boehringer ingelheim company actively daniele de cillis enthusiastic time supports social responsibility says spent academy camp expe knows something pre rienced much joy happiness zest scribed part corporate culture life young people first sight haveanything boehringer ingelheim smile lives responsibility daniele de cillis office little reason laugh boehringer ingelheim boehringer ingelheim subsidiary milan six given support needed youth venture months superiors supported mained fully employed boehringer ingelheim programmes boehringer ingelheim continued receive salary says social entrepreneurs making health launched convinced actively involved social time ive opportunity years charity organisation ashoka youth venture programmes enterprise enriches lives employees dedicate something completely different supported work socalled social entrepreneurs designed give adolescents enhances professional skills daniele adds worldwide business models aim contribute young adults ages head sales training spent six months work positive change society services provided social twelve chance change ing dynamo academy social enterprise involvement charity work way entrepreneurs include scholarships advice entrepreneurial lives better part dynamo camp one largest restricted break work dynamo academy issues global network experts developing implementing charity organisations italy six years spending free concrete ideas focus fields time hospital clown putting costume ranging nutrition sport well workplace environ recreation therapy camp heart tus wig perform silly tricks seriously ill mental protection social action cany children serious chronic illnesses children daniele even uses holidays enter trainees boehringer ingelheim take oneweek holiday without tain give children little happiness employees children driving parents free charge back take away sadness little says boehringer ingelheims force behind project daytoday life bring daniele reward hundredfold greater making health initiative memories beautiful holiday also boehringer ingelheim celebrated idea normal life possible says daniele dedicated making health th anniversary company used first foremost however manager runs occasion launch making health dynamo academy generates money camp making health projects italy part initiative running today countries aim improve able ensure camp initiative launched boehringer ingelheim health society end making run increasingly sustainable manner nonprofit organisation ashoka making health supports social entrepreneurs money necessary among things health supports work social entre field healthcare order identify new generated dynamo academy training preneurs healthcare field worldwide approaches push ahead develop centre annexed camp offers corporate team ment together close collaboration ashoka activities example danieles job daniele invests around quarter work fundamental achieving aim revamp academys existing range seminars boehringer ingelheim projects years boehringer ingelheim company actively daniele de cillis enthusiastic time supports social responsibility says spent academy camp expe knows something pre rienced much joy happiness zest scribed part corporate culture life young people first sight havename albert boehringer occupation founder company year birth location ingelheim germany independence meant albert boehringer successful grow ones efforts achieve goal focused early stage research employee satisfaction sense family serving humankind living n e p e n e n c e independent familyowned business key focus boehringer ingelheim longterm sustainable action achieve goal requires sound wearing plain suit traditional loden example bought first car second financing organic corporate growth boehringer ingelheims corporate jacket stands thoughtfully entrance hand shortage coal culture based values applied since company c h boehringer sohn chbs watching production risk simply acquired lorries leavingf tohuen fadcetodr yin supply customers disused colliery employees always companys latest product cardio given top priority first world war vascular drug sympatol modestlooking example continued pay salaries man factory gate none enlisted army intro yearold councillor commerce albert duced health insurance scheme company boehringer companys founder owner employees early offered paid leave com lost thought pauses moment con pany pension scheme inexpensive housing sider long journey behind factory workers lots bene fits far common days chbs parent company todays boehringer ingelheim difficult times key principle albert boehringer recognised hyperinflation germany importance good people working french occupation rhineland like nephew robert boehringer first world war following launch ran company first world war respiratory product lobelin succeeded heinrich wieland cousin albert boehringers making another highly effective drug sympatol wife helene later receive nobel available patients success drugs prize chemistry also important albert secured financial independence family boehringer know company owned company run members family early stage therefore sons soninlaw joined son family entrepreneurs mann company today boehringer von baumbach heim southwest germany started business families fourth generation continue much simpler circumstances pro manage companys fortunes producer duction chemical compounds tartaric tartaric acid nieder ingelheim developed lactic acid years later however today inter nationally successful pharma clear albert boehringer inherited ceutical company perhaps albert boehringer right combination business talents young envisioned development watched entrepreneur invested money tradi lorries leaving factory laden sympatol tional virtue thrift native swabia specific areas well thoughtserving boehringer humankind ingelheim maintains hubertus von baumbach becomes member board managing independence directors responsibility finance years christian boehringer appointed chairman shareholders committee wearing plain suit traditional loden example bought first car second jacket stands thoughtfully entrance hand shortage coal c h boehringer sohn chbs watching production risk simply acquired owner family withdraws following death lorries leaving factory supply customers disused colliery employees always management death albert ernst hubertus liebrecht oversees boehringer julius companys latest product cardio given top priority first world war company julius liebrechts son liebrecht appointed vascular drug sympatol modestlooking example continued pay salaries shareholders committee hubertus appointed chairman board chairmanship taken chairman board directors man factory gate none enlisted army intro erich h von baumbach directors yearold councillor commerce albert duced health insurance scheme company company goes boehringer companys founder owner employees early offered paid leave com international lost thought pauses moment con pany pension scheme inexpensive housing sider long journey behind factory workers lots bene fits far common days albert boehringer pur chbs parent company todays boehringer chases tartar factory alberts brother ernst niederingelheim laying ingelheim difficult times key principle albert boehringer recognised boehringer joins foundation albert boehringer julius liebrecht mar board directors hyperinflation germany importance good people working presentday company jr son com ried ilse daughter panys founder companys founder joins french occupation rhineland like nephew robert boehringer joins board board directors first world war following launch ran company first world war directors respiratory product lobelin succeeded heinrich wieland cousin albert boehringers making another highly effective drug sympatol wife helene later receive nobel available patients success drugs prize chemistry also important albert independence fundamental independent boehringer independence unique independence stands secured financial independence family boehringer know company protecting business ingelheim enables focus opportunity bolder familys commitment sus values key guarantee generating longterm professionally personally tained profitability creating owned company run members family early stage ing integrity decision making sustainable healthcare solu companies provide value based innovation therefore sons soninlaw joined safeguard patient safety tions customers autonomy develop enables establish innov son family entrepreneurs mann company today boehringer von baumbach reduces need react fre powerful brand way ative technologies accord sophie fontez regional heim southwest germany started business families fourth generation continue quently external market boehringer ingelheim ance companys guid pharmacovigilance head much simpler circumstances pro manage companys fortunes producer asia middle eastnorth fluctuations ing principles leitbild africa renato camera duction chemical compounds tartaric tartaric acid nieder ingelheim developed arthur mendonca senior brand manager dr silke ldtke boehringer ingelheim regional business manager head bioanalysis lactic acid years later however today inter nationally successful pharma brasil emerging markets area biomarkers development clear albert boehringer inherited ceutical company perhaps albert boehringer management germany right combination business talents young envisioned development watched entrepreneur invested money tradi lorries leaving factory laden sympatol tional virtue thrift native swabia specific areas well thoughtserving boehringer humankind ingelheim maintains hubertus von baumbach becomes member board managing independence directors responsibility finance years christian boehringer appointed chairman shareholders committee wearing plain suit traditional loden example bought first car second jacket stands thoughtfully entrance hand shortage coal c h boehringer sohn chbs watching production risk simply acquired owner family withdraws following death lorries leaving factory supply customers disused colliery employees always management death albert ernst hubertus liebrecht oversees boehringer julius companys latest product cardio given top priority first world war company julius liebrechts son liebrecht appointed vascular drug sympatol modestlooking example continued pay salaries shareholders committee hubertus appointed chairman board chairmanship taken chairman board directors man factory gate none enlisted army intro erich h von baumbach directors yearold councillor commerce albert duced health insurance scheme company company goes boehringer companys founder owner employees early offered paid leave com international lost thought pauses moment con pany pension scheme inexpensive housing sider long journey behind factory workers lots bene fits far common days albert boehringer pur chbs parent company todays boehringer chases tartar factory alberts brother ernst niederingelheim laying ingelheim difficult times key principle albert boehringer recognised boehringer joins foundation albert boehringer julius liebrecht mar board directors hyperinflation germany importance good people working presentday company jr son com ried ilse daughter panys founder companys founder joins french occupation rhineland like nephew robert boehringer joins board board directors first world war following launch ran company first world war directors respiratory product lobelin succeeded heinrich wieland cousin albert boehringers making another highly effective drug sympatol wife helene later receive nobel available patients success drugs prize chemistry also important albert independence fundamental independent boehringer independence unique independence stands secured financial independence family boehringer know company protecting business ingelheim enables focus opportunity bolder familys commitment sus values key guarantee generating longterm professionally personally tained profitability creating owned company run members family early stage ing integrity decision making sustainable healthcare solu companies provide value based innovation therefore sons soninlaw joined safeguard patient safety tions customers autonomy develop enables establish innov son family entrepreneurs mann company today boehringer von baumbach reduces need react fre powerful brand way ative technologies accord sophie fontez regional heim southwest germany started business families fourth generation continue quently external market boehringer ingelheim ance companys guid pharmacovigilance head much simpler circumstances pro manage companys fortunes producer asia middle eastnorth fluctuations ing principles leitbild africa renato camera duction chemical compounds tartaric tartaric acid nieder ingelheim developed arthur mendonca senior brand manager dr silke ldtke boehringer ingelheim regional business manager head bioanalysis lactic acid years later however today inter nationally successful pharma brasil emerging markets area biomarkers development clear albert boehringer inherited ceutical company perhaps albert boehringer management germany right combination business talents young envisioned development watched entrepreneur invested money tradi lorries leaving factory laden sympatol tional virtue thrift native swabia specific areas well thoughtgroup management report boehringer ingelheim annual report group management report group management report information group companies report economic position report postbalance sheet date events risk report report expected developments information group companies group management report information group companies groups business model boehringer ingelheim researchdriven group com buscopan dulcolax pharmaton boehringer panies dedicated research development pro ingelheim also one largest suppliers veterinary duction marketing pharmaceuticals high drugs worldwide business ingelvac circoflex therapeutic value human medicine animal currently topselling brand health boehringer ingelheim group consists companies employs around people another field growth company development net sales amounting eur billion boehringer production biopharmaceuticals business ingelheim one top pharmaceutical companies focusing contract manufacturing biosimilars worldwide boehringer ingelheims activities consist addition research development new biological following businesses prescription medicines con sumer health care animal health bio pharmaceuticals industrial customers net sales business millions eur prescription medicines business continues prescription medicines mainstay companys business medicinal products boehringer ingelheim become established standard treatments diseases respiratory tract cardiovascular system central nervous sys consumer health care tem addition metabolic disorders infectious diseases important medicinal products supplied boehringer ingelheim include spiriva treat ment chronic obstructive pulmonary disease copd animal health micardis treatment hypertension two drugs pradaxa prevention stroke patients suffering atrial fibrillation thromboembolic disorders trajenta treatment type dia biopharmaceuticals betes reported continuous growth since launch support boehringer ingelheims positive business performance industrial customers sales companys bestselling products consumer health care business include drugs mucosolvan boehringer ingelheim annual report group management report net sales region millions eur research development rd line boehringer ingelheims mission statement primary goal develop innovative drugs thera pies treatment diseases yet satisfactory treatment available aim times make major contribution europe areas need treatment high occupy leading position major indication areas asia australia africa order achieve goals ensure important americas aaa technologies remain state art systematically examine new technological approaches regular contact global network academic groups public research institutes biotech companies provides boehringer drugs boehringer ingelheim one europes leading ingelheim access latest developments providers contract manufacturing biotechnically findings addition regularly supplement prod manufactured pharmaceutical products devel uct portfolio specific inlicensing joint ven oped manufactured facilities biberach ger ture agreements many vienna austria fremont usa using cell cul tures microorganisms employed average people rd ites majority boehringer ingelheims sales achieved americas europe total around eur billion invested worldwide around groups net sales generated research development new drugs usa japan germany net sales around e ur equivalent groups net sales thus billion asiaaustraliaafrica aaa region level prior year accounts groups net sales growing importance addition established financial year addition giotrif regions primarily emerging markets russia nonsmall cell lung cancer also pradaxa treat brazil india china africa particular ment prevention deep vein thrombosis pulmo growing significance individual emerging markets nary embolism launched number specific boehringer ingelheim achieved growth rates markets striverdi olodaterol respimat chronic excess obstructive pulmonary disease copd received regulato ry approval way company continues boehringer ingelheims focus research de renew expand product portfolio velopment rd innovative medicines therapies ultimate goal secure future growth phar maceutical business products companys research evelopment boehringer ingelheim operates global research network large sites germany biberach usa ridgefield austria vienna information group companies research development expenditure eur million net sales prescription medicines expenditure eur million prescription medicines net sales average number employees investments tangible assets without investments infrastructure eur million human pharmaceuticals chronic obstructive pulmonary disease copd boehringer ingelheim carried research develop volved patients particular study ment businesses prescription medicines showed comparable time first exacerbation copd consumer health care facilities usa ger comparable tolerance spiriva tiotropium many austria italy japan formulations respimat handihaler study also demonstrated use spiriva respimat key focus research work spiriva handihaler similar impact surviv following indication areas al important survival advantage shown previous uplift trial treatment respiratory diseases spiriva handihaler compared cardiometabolic disorders cardiovascular control treatment results basis submit etabolic disorders ting marketing authorisation application spiriva oncology respimat usa respimat inhaler propel diseases central nervous system lantfree soft mist inhaler used stand immunology ard application device future respiratory products infectious diseases using olodaterol respimat addition expenditure rd prescription medicines account current treatment phase iii trial involving copd ed net sales generated business patients showed statistically significant improvement lung function olodaterol highly selective longacting key studies data financial year pre beta agonist laba boehringer ingelheims research sented pipeline olodaterol approved use brand name striverdi respimat first time boehringer ingelheim one worlds leading phar maceutical companies treatment respiratory new data tiotropium asthma demonstrate diseases addition successful product date tiotropium respimat effective treatment research tiotropium availa symptomatic asthma patients regardless allergy ble ten years brand name spiriva status age smoking behaviour bronchodilator reac company comprehensive research develop tion tiotropium given daily via respimat signifi ment pipeline cantly improved lung function tiotropium safety performance respimat asthma patients remained symptomatic despite tiospir one largest trials ever conducted treatment inhaled corticosteroids ics long boehringer ingelheim annual report group management report acting beta agonists laba focus two repli demonstrated specific highly selective antibody cate doubleblind parallel group trials tiotropium fragment fab potential duced asthma exacerbations patients remained needs proven within clinical studies symptomatic despite treatment least icslaba medicines regardless whether exhibited allergic indication area metabolic disorders focus symptoms research development drugs treatment diabetes patients remained symptomatic despite treatment ics achieve statistically significant clini key trials linagliptin carmelina de cally relevant improvement asthma control means signed investigate effect linagliptin compared oncedaily dose tiotropium confirmed standard treatment terms cardiovascu data mezzotinaasthma phase iii twin studies lar renal microvascular events well current approval procedure use tiotropium asth c arolina trial eventdriven cardio initiated european union eu sec vascular endpoint trial directly compares dpp ond half inhibitor linagliptin sulfonylurea glimepiride addition respiratory diseases field cardio end first half suc metabolic disorders important research field cessfully completed number key trials inves boehringer ingelheim among things expanded tigational compound empagliflozin phase iii clinical development programme pradaxa dab empar eg clinical trials programme programme igatran etexilate field focused type diabetes involved patients included ten multinational clinical trials remedy resonate recover clinical recruitment completed empareg trials demonstrated pradaxa effective outcome eventdriven cardiovascular endpoint time exhibits favourable safety profile trial designed assess effect empagliflozin com treatment acute deep vein thrombosis pulmonary pared standard treatment involving people embolism subsequent secondary prevention well type diabetes high cardiovascular risk end boehringer ingelheim announced indication area oncology boehringer ingelheim two new phase iii trials planned respect involved research development new types esus carry research determine efficacy cancer treatment offer patients added thera safety pradaxa preventing another stroke peutic value contribute improvement patients whose first stroke embolic origin quality life unknown source whereas redual pci address question efficacy safety pradaxa pre data luxlung phase iii trial show venting blood clots patients atrial fibrillation patients received giotrif afatinib still received stent result narrowing blood alive one year later showed tumour progression vessels supply blood heart case patients treated chemotherapy new results con improve patient safety boehringer ingelheim firm findings companys previous luxlung working antidote reverse anticoagula phase iii trial demonstrate giotrif superi tion effect pradaxa initial results first study standard chemotherapies patients egfr healthy volunteers phase clinical trials erbb mutationpositive nonsmall cell lung cancer information group companies nsclc addition possible demonstrate animal health treatment giotrif patients type boehringer ingelheims research animal health lung cancer leads significant delay tumour business focuses research development progression also improved quality life novative vaccines primarily protect livestock com authorities eu large number panion animals addition pharmaceutical products countries europe americas asia ap company invested eur million proved giotrif drug also approved research development new products set usa brand name gilotrif ting new rd facilities equivalent net sales generated companys animal health nintedanib first treatment lung cancer business combination chemotherapy extend life patient initial treatment failed facilities usa germany mexico china year shown results lume japan denmark india netherlands focus lung phase iii clinical trial basis research new drugs development future sults boehringer ingelheim submitted application therapeutic solutions since many vaccines based european medicines agency ema author local pathogens pathogen variants imperative ities second half approval present key sales regions nintedanib research development production facilities startverso phase iii programme demonstrated european research centre animal vaccines faldaprevir combination pegylated interferon hanover began operations financial year ribavirin proved effective safe large num company invested eur million ber hepatitis patients infected genotype includ boehringer ingelheim veterinary research centre ing patients advanced liver disease pa bivrc tients received previous treatment early treatment success therefore shorter duration china activities first asian research de treatment achieved company submitted applica velopment centre veterinary medicine ex tions us food drug administration fda panded end boehringer ingelheim al ema authorities worldwide ap ready invested total eur million investments proval faldaprevir demonstrate companys commitment intention strengthen position animal health consumer health care business boehringer ingel heim successfully launched products boxagrippal financial year boehringer ingelheim received vaprino german market substances european market authorisation three new drugs available overthecounter medication veterinary medicine pexion treatment epilep obtained without prescription boxagrippal contains sy dogs semintra treatment chronic kidney first combination ibuprofen pseudeoephedrin disease cats prozinc insulin treatment consumer health care market vaprino secre type diabetes mellitus cats usa new vaccine tion blocker therapy acut diarrohea adults approved cats prevent rabies vaccine years age prevention influenza dogs vaccine prevention salmonellosis typhimurium swine first vaccine cattle europe bovela bvd submitted ema clinical programme boehringer ingelheim annual report group management report new vaccine porcine reproductive respiratory syn challenging terms technology pro drome prrs europe completed cesses involved production guidance third party management human pharmaceuticals pm department network contract management global production network consisted organisations cmos focuses manufacture facilities countries spread production products already established market sites group operates pharmaceutical chemical advanced stage life cycle ensures relia biopharmaceutical production units one pro ble competitive supply prescription medicines duction unit medicinal devices highest priority consumer health care products accordance sites provide reliable highquality sup relevant requirements ply products customers within group external industrial clients local presence growth markets production pm network enables us provide high october boehringer ingelheim announced would level flexibility position respond optimal closing production us subsidiary ben ly local needs venue laboratories inc bedford ohio end despite close collaboration fda ut september boehringer ingelheim inaugurated ex commitment workforce investments tension production facility building designed improve facilities possible secure lev accommodate chemical research development el sustainable production required particularly laboratory zhangjiang hitech park shanghai market environment changed significantly china total investment cost eur million site zhangjiang become one boehringer ingel following inspection manufacturing process heims important centres asiapacific region production site ingelheim us food size workforce increased drug administration issued warning letter aim triple production capacity extend resulted concerns relating compliance ing site make possible add new competences current good manufacturing practice cgmp expand capacity set effective supply chain boehringer ingelheim taking matter seriously project includes packaging centre enough result warning letter comprehensive initia space accommodate latest packaging systems new tive launched response fdas con quality control laboratories automatic warehous cerns action plan filed fda cur ing logistics area reliable highquality deliveries rently implemented fully comply cgmp market launch new medicinal products standards important technologies solid forms tablets liquids syrup anticipated production capacity chemical pharmaceutical production facilities million packages increasing mil product launches grouped together pharma lion ceutical chemical manufacturing pcm division acts interface development new building also erected centre activities series production division responsi competence moved waigaoqiao ble compliance high quality standards zhangjiang focus work carried rd organising new product launches production chemical laboratory operation since innovative products entire life cycle process optimisation performance information group companies analytical tests pharmaceuticals chemical inter company shanghai china build cgmp bioparma mediates purchased boehringer ingelheims ceuticals facility new site provide variety strategic partners china clinical development services chinese multi national customers facility equip biopharmaceuticals ment required process development production addition manufacturing proprietary actilyse accordance cgmp scheduled completion metalyse imukin beromun development early boehringer ingelheim planning invest products boehringer ingelheims biopharmaceutical pro eur million create jobs duction facilities fremont usa biberach germany vienna austria also globally recognised contract boehringer ingelheims year strategic alliance manufacturers thirdparty clients company cov pharmaceutical companies rochegenentech ers entire biopharmaceutical process chain ge celebrated october joint development work netic development cell followed manufacturing carried companies resulted successful filling finished pharmaceutical product products actilyse metalyse imukin product launch global market supply beromun helped patients worldwide many years collaboration contract manufacturing largescale cell culture facilities packing facilities addition development products also included biberach successful process validation production brand product activase pradaxa antidote completed applica boehringer ingelheim american market roche tion approval molecule planned genentech animal health financial year boehringer ingelheim success partnership taizhou china medical city fully concluded new contracts contract manufactur boehringer ingelheim announced august construc ing business including production agreement peri tion production facility veterinary vaccines od several years leading swiss pharmaceutical province jiangsu china joint venture includes company recombinant protein successful total investment eur million completion spection fda production site vienna fda production facility employ workers approval new isolator line biberach site scheduled june help joint venture given asceptic production biopharmaceuticals develop leading force chinese animal hus boehringer ingelheim also negotiated development bandry sector future facility produce vaccines production agreements pharmaceutical com primarily treatment swine poultry diseases panies molecules produced cell cul china asian markets investment ture production facilities biberach fremont lines longterm commitment china swedish company sobi boehringer ingel heim received us fda european ema ap environmental employee protection proval production facility vienna pro concern social ecological issues firmly duction brand product kineret inhibits anchored boehringer ingelheims corporate philosophy biological activity interleukin thus major many years crucial importance compa impact many inflammatory disorders nys longterm development high value placed issues also reflected mission statement boehringer ingelheim signed cooperation agreement protection employees facilities zhangjiang biotech pharmaceutical base environment addition sustainable pru boehringer ingelheim annual report group management report dent use natural resources promotion envi expertise companys facilities co ronmental awareness key components ordinating projects international level observing social ecological concerns way co emissions index calculated ensure enjoy sustainable business success annual basis already indicates trend right direc boehringer ingelheim demonstrated commitment tion ultimately enable us achieve ambi responsibility participating responsible care tious target initiative world chemicals association since top priority boehringer ingelheim given health binding standards environmental protection health safety employees reflected high occupational safety long implemented global safety standards guidelines well throughout group companies internal guide implementation safety culture groupwide lines reflect respective countryspecific legal require initiative safe launched aims ments significantly exceed many cases reduce number work accidents since rolled large number international division environment health safety ehs facilities efforts designed achieve goal sponsible introducing reviewing internal envi planned mena middle east north africa ronmental occupational safety guidelines compli region example smaller facilities latin ance standards status environmental america employee protection examined part regular audits order continuously identify potential areas part initiative members senior management improvement total internal ehs audits per entire workforce play key role proactively tak formed throughout group financial year ing responsibility safety safety colleagues accident rate accidents example continuous improvement environ per million hours worked remained sim mental protection iso certification suc ilar level prior year cessfully begun ingelheim site ingelheim active ingredients drugs produced employee reporting years company launched comprehensive previous years boehringer ingelheims workforce examination decontamination ground increased financial year average number adjacent plant premises continued people employed boehringer ingelheim year technical progress improved information mean equivalent increase com problems nature analysed pared prior year accurately previously case experts fields geochemistry environmental toxicology en average number employees region gineering consulted advice implementing americas measures europe asiaaustraliaafrica aaa boehringer ingelheim set ambitious target cutting co emissions achieved including potential energy savings result increase workforce new admin reductions emissions promoting exchange istration building erected headquarters information group companies ingelheim boehringer ingelheim invest eur mil companys performance individual targets lion new building accommodate em achieved individual employee part con ployees building scheduled completion tinuous communication process employee end superior individual targets agreed cur rent year beginning year achievement boehringer ingelheims employees important fac targets ultimately direct effect variable tor successful future development company salary component extensive voluntary social benefits accordingly particularly committed actively de company pension scheme preventive health veloping supporting employees ensure examinations round attractive salary system ideally equipped deal challenges ahead opinion places us good competitive position part comprehensive training system place great importance acquisition technical skills members senior management boehringer ingelheim also promotion social skills also receive salary component linked companys longterm success variable salary component apprenticeship vital source qualified young people geared towards attainment longterm company traditionally one boehringer ingelheims special targets concerns purpose graduates choose among different career paths companys german facili build commitment innovation vi ties germany alone boehringer ingelheim invests tality workforce regard good balance around eur million year career training tween career private life one keys corpo addition specific skills apprentices encouraged rate success satisfaction workplace efforts act independently creative take responsibil make support members workforce ity financial year employed appren clude provision services bifit fitness tices germany programme medical care comprehensive advice sup porting family providing child care parttime work integral part corporate strategy talent man flexible working hours services kind based agement particularly important aim pro local requirements individual countries gramme right people right place right time enables employability career november boehringer ingelheim received development employee development poten corporate health award third time emphasising tial identified specially prepared strategically high value corporate health management enjoys important positions early stage behaviour boehringer ingelheim future boehringer ingel performance delivered employee assessed heims aim continuously expand corporate health purpose appropriate distinctions made management services new area become terms salary career development opportunities involved therefore healthy leadership addition strong corporate culture approach enables us recruit highly qualified employees even corporate citizenship competitive business environment ensure decades boehringer ingelheim actively remain loyal boehringer ingelheim long term volved areas extend far beyond business interests social responsibility commitment soci salary system boehringer ingelheim includes ety whole cover wide range issues boehringer competitive basic salary variable salary component ingelheim firmly anchored corporate phi amount variable component based losophy future well commitment boehringer ingelheim annual report group management report wellbeing patients employees families th autumn run ingelheim provided opportu focus many initiatives also support par nity employees become involved ticipation many projects designed help event dedicated good cause company needy activities actively encouraged particular donates sum money social projects every partic ly countries regions business ipant sporting event example boehringer ingelheims social commit online webbased changemaker competition ment implementation un convention also launched competition encourages mem rights persons disabilities action plan bers general public send new ideas ways specify goals ideas enable us im healthcare improved poorly supported plement un convention areas within organisa environments addition example making tion bring change workplace health partnership also includes variety addi design barrierfree access social benefits tional initiatives projects addition longterm initiatives boehringer open differing ideas opinions ingelheim also provides help urgently needed drawing great diversity experience cultural example boehringer ingelheim donated backgrounds different characters personalities flood victims eastern parts germany well possible boehringer ingelheim remain true victims devastating typhoon haiyan phil motto value innovation desire create ippines amount philippines made availa working environment open diversity dif ble german red cross emergency aid phil ferences one fundamental pillars cor ippine subsidiary boehringer ingelheim also supported porate culture diversity inclusion help us live various local aid organisations donations cash core values respect trust empathy passion medicines cause values important boehringer ingel heim response corporate charter diversi social commitment employees also encouraged ty germany companys first nationwide diversity boehringer ingelheim third year day held june programme since partnership set making events focused many aspects diversity health initiative boehringer ingelheim ashoka international nonprofit organisation boehringer ingelheim active supporter major part social commitment research science culture many years longterm aim partnership promote health people partnerships academic institutions serve around world including f amilies social line groups systematic focus research develop environment identifying implementing promising ment addition supporting sponsoring scientific solutions dealing health problems order activities company presents scientists awards achieve goal support given selected boehringer ingelheim fens research award social entrepreneurs worldwide pushing ahead neuroscience moreover company awards effective longterm solutions healthcare field heinrich wieland price annually outstanding research end boehringer ingelheim em active biological molecules systems well ployees participate making health ini clinical relevance tiative countries report economic position report economic according consumer price index aver position age inflation rate germany decelerated reasons still existing price increases higher costs energy food entire macroeconomic environment eurozone annual inflation rate following euro crisis global economy stabilised compared previous year growth rate thus level previous years result previous financial year performance expansionary monetary policy upswing us dollar usd japanese yen jpy countries however yet selfsustaining global key currencies boehringer ingelheim varied dustrial production increased moderately driven euro exchange rate us dollar showed lateral strengthened industrialised nations contrast slow movement ranging usdeur march rate economic growth emerging usdeur december japanese yen exchange developing countries continued foreign trade rate dropped significantly euro course countries actually declined slightly towards end starting rate january jpyeur year major drivers positive trend global rising jpyeur end december economy primarily positive investor sentiment usa economic recovery japan euro growth global pharmaceutical market zone large extent moved recession support affected expiry patents prod ed strong german economy continuing stabi ucts earning billions sales greater competition due lisation euro countries generic products measures taken restrict costs governments health authorities regained slight increase growth rate global economy momentum second half grew expected series early indicators around overall performance primar points continuing recovery economy im ily due primarily contributions emerging provement confidence seen case com countries cases doubledigit growth rates panies consumers industrialised nations whereas acceleration production growth recovery course business housing market seen usa low rate focus boehringer ingelheims business activities growth continues expected eurozone weak securing groups independence ening growth also expected japan since fiscal basis achievement longterm policy measures responsible economic upswing sustainable development company accompanied expire coming year stable profits solid financing economic output germany last year marked number challenges face indicators increase consumer spend transition year group result numer ing point continuation upswing signalling ous measures taken changes made end weak phase positive results research development activities basis business performance never positive emerging trend seen todays theless laid years come perspective likely continue coming year growth expected due primarily net sales amounted eur million increase consumer spending represents change compared boehringer ingelheim annual report group management report exchange rate developments foreign exchange letter offset effects resulting markets associated exchange rate effects measures initiatives increase efficiency reduce negative impact currency adjusted boehringer ingel costs introduced last year groups heims growth rate stood means despite turn net sales increased declines sales products lost exclusivity key figures eur million change countries eg micardis sifrol viramune net sales company continues growth trend operating income return net sales sales eur million thus total sales americas region remained companys important sales market decline importance results operations region compared previous year results primarily boehringer ingelheims business activities devided change eurusd exchange rate prescription medicines consumer health care associated lower sales currency adjust animal health biopharmaceuticals industrial cus ed europe boehringer ingelheim generated net sales tomers amounting eur million equivalent net sales businesses currency total sales growth currency eur million change adjusted adjusted compared previous year prescription medicines global sales amounting eur million attrib consumer health care utable asiaaustraliaafrica region share animal health group sales thus approximately equivalent biopharmaceuticals previous year net sales region declined industrial customers sales adjusted currency effects however increase achieved prescription medicines net sales region currency share overall sales prescription medi eur million change adjusted cines key pillar boehringer ingelheims activities americas net sales amounted eur million europe equivalent change compared asiaaustraliaafrica aaa previous year currency adjusted overall satisfied development previous years spiriva used treat sales despite difficult year growth chronic obstructive pulmonary disease copd achieved basis established products bests elling product reporting period generated newly launched products adjustment exchange sales eur million thus level rate effects compared previous year previous year largest sales market usa sales promising innovative products pipeline serve af spiriva increased resulting total firm actions company sales eur million boehringer ingelheim generated operating income based sales second important product amounting eur million factors affecting boehringer ingelheim icardis drug treatment result closure site bedford usa high blood pressure generated sales amounting additional expenses resulting fda warning eur million thus previous report economic position years level decline expected result aaa region achieved net sales eur million ed loss exclusivity markets equivalent share region report ed slight decline compared previous launched anticoagulant pradaxa year results large extent currency increase sales eur million proved related decline sales japan currency adjusted driver growth growth achieved region japan boehringer ingelheim generated net sales eur mil net sales eur million change lion corresponds change compared spiriva previous year micardis pradaxa consumer health care combivent remained difficult market environment sales consumer health care business terms regional distribution sales region currency adjusted compared previous europe market reporting increase year business boehringer ingelheim generated prescription medicine business region asia sales amounting eur million australiaafrica aaa contrast reported declines sales compared previous year bestselling products consumer health care business mucosolvan buscopan net sales region dulcolax pharmaton products generated eur million change sales eur million previous americas year buscopan net sales eur million europe biggest seller terms growth mucosolvan en asiaaustraliaafrica aaa joyed sales increase reporting sales amounting eur million previous year americas share far largest exceeded million mark zantac bisolvon market boehringer ingelheim generated sales amounting eur million equivalent change net sales eur million change currency adjusted compared buscopan previous year greatest impact development dulcolax americas sales performance im mucosolvan portant market usa sales eur mil pharmaton lion decreased primarily result unfavourable exchange rate development considering region whole europe generated highest net sales eur million corresponds europe second largest market accounted share share global net sales consumer health sales amounting eur million care business business europe grew growth market region europe achieved currency adjusted germany growth currency adjusted compared important market boehringer ingelheim business performance europe driven primarily growth generated uk contributed eur million germany largest market growth americas region second largest sales market stagnated total sales amounting eur million consumer health care business ended financial boehringer ingelheim annual report group management report year slight decline currency ad eur million whereas sales usa largest justed compared previous year achieved market remained previous years level canada total net sales eur million corresponds brazil reported decline business share regions total chc business far largest market usa remained stable com region europe boehringer ingelheim pared reported slight growth financial year currency adjusted whereas net sales germany aaa region ended financial year net remained stable level previous year france sales amounting eur million thus second largest european market performed currency adjusted previous positively year market thus accounted boehringer ingelheims consumer health care business main biopharmaceuticals driver decline japanese market since financial year boehringer ingelheim net sales declined due currency effects manages biopharmaceuticals business separate eur million division consists contract manufacturing biosimilars research development new bio animal health logical active ingredients sales amounted sales business animal health products eur million represented decline increased eur million thus result weak contract manufacturing business currency adjusted level pre compared previous year vious year largest percentage sales attributable livestock products eur million ac industrial customers sales counted livestock segment equivalent industrial customer business encompasses share eur million bestselling prod thirdparty business field pharmaceutical pro uct last year swine vaccine ingelvac circoflex duction contract manufacturing business business companion animal segment generated fur pharma chemicals net sales amounting eur mil ther eur million corresponds share lion generated equivalent growth currency adjusted net sales eur million change ingelvac circoflex presentation expenditure income metacam financial year boehringer ingelheims operat ingelvac prrs ing expenses dropped eur million repre duramune sents change compared previous year eur million material costs remained level largest contribution growth came previous year eur million represents emerging markets aaa region region grew material costs share total sales personnel currency adjusted overall eur mil costs amounted eur million lion chinese market particular net sales increased thus slightly level eur million eur million result personnel expenses share came share business net sales ameri amortisation dropped compared pre cas largest region reported slight decline vious year amounted eur million op currency adjusted compared previous year erating expenses declined yearonyear eur report economic position report postbalance sheet date events risk report million among things cost block result boehringer ingelheims international orien cludes commission licence payments de tation developments foreign exchange rate mar pendent sales reduction operating ex kets considerable impact companys finan penses compared previous year particular results cial performance importance us business exchange rate effects well sustainable ef associated supply relationships mean ex ficiency initiatives instigated last year operating income change rate development us dollar constitutes despite situation us subsidiary ben venue lab greatest individual risk within framework group oratories inc well action taken result wide financial reporting foreign exchange risk calculat fda warning letter level previous ed hedged derivative financial instruments year increased compared nature scope measures set eur million group guidelines regularly discussed rele vant committee standardised process reporting period financial income totalled eur million eur million compared investments great importance boehringer ingel previous year largely attributable heims future continuous investment requirement interest effects within pension commitments companys longterm development forms ba sis profitable growth businesses income taxes developed line result operating activities increasing total eur million invested tangible eur million intangible assets year review tax expenses amounted eur million must continue meet positive demand respimat taken consideration provisions soft mist inhaler company moved ahead german commercial law shareholders personal taxes expansion production capacity dortmund arising group business activities may recog ingelheim sites investments amounting nised tax expenses instead taxes presented eur million respimat soft mist inhaler part withdrawals group equity taking ex manufactured boehringer ingelheim microparts traordinary effect account actual tax ratio gmbh dortmund filled corresponding markedly higher figure shown profit pharmaceutical active ingredients ingelheim site loss statement global distribution important growth market china boehringer ingelheim invested financial year net income boehringer eur million expansion production facili ingelheim group totalled eur million ties building accommodate chemical rd thus level previous year eur mil laboratory shanghai china research development lion fields human animal medicine also main top priority boehringer ingelheim future financial position end additional investments made rd boehringer ingelheims financial management instru facilities germany austria usa ments methods aimed securing liquidity limit ing financial economic risks optimising cost cash flow stood eur million con capital suitable capital structure finan stitutes decline compared mainly due cial activities therefore geared towards supporting higher level receivables compared previous companys business strategy year cash flow operating activities fell eur mil boehringer ingelheim annual report group management report lion eur million despite decrease pre year review despite decreased liabilities due vious years investments financed entirely banks also remained stable eur million funds generated company balance sheet respective balance sheet ratios total eur million invested tangible assets round positive picture already shown finan eur million intangible assets cash flow cial position results operations combined operating activities exceeded cash flow investing evaluation net assets financial position results financing activities resulted increased securi operations shows boehringer ingelheim ties liquid funds yearend eur million soundly financed profitable company summary emphasised existing report postbalance liquidity financial structure high cash flow operating activities prerequisites sta sheet date events ble continuation business activities suc cessful implementation strategy fulfilled since end financial year net assets come aware events material significance financial year boehringer ingelheims total group companies could lead assets amounted eur million increase appraisal net assets financial position results eur million compared previous operations year tangible intangible assets totalled eur mil lion fully covered consolidated equity risk report end financial year financial assets reached figure eur million eur million risk opportunity management higher previous year inventories change aim risk management system implemented remained virtually unchanged eur mil boehringer ingelheim identify businessspecific risks lion eur million trade accounts receivable particular risks jeopardise continued ex rose eur million eur million istence company early possible assess liquid funds including nonfixed securities stood reduce reasonable level means suit eur million eur million able measures due abovementioned changes cash cash assessing risks context holistic risk equivalents group equity amounted eur mil management also endeavour take account lion long term addition equity pen resulting opportunities opportunity management sion provisions longterm liabilities also available based companys strategies objectives addi group three items totalled eur mil tion individual businesses operating business lion equivalent total assets units integral part groupwide planning consequently longterm disposable capital covers management systems responsible busi tangible tangible assets inventories trade accounts nesses functions bear direct responsibility ear receivable provisions eur million ly systematic identification analysis use op level previous year liabilities hardly changed portunities boehringer ingelheim researchdriven innovative company current rd activities risk report naturally considered relevant opportunity detailed monitors quantifies risks regular intervals description projects illustrated rd makes predictable future business means chapter relevant hedging strategies appropriate financial instruments forward exchange contracts persons responsible key businesses func sultant risks subsequently designated con tions included process calculating assess crete therefore controllable ing risks groupwide risk information system en sures identified risks analysed assessed credit countryspecific risks carefully following appropriate classification var boehringer ingelheim exposed various credit ious categories adequate countermeasures initiated countryspecific risks result international busi implementation consistently monitored ness activities portfolio trade accounts ceivable trade accounts payable identi year review internal auditing performed tar fied extraordinary risks group beyond geted routine audits well extraordinary audits around usual level sector applies possible de world addition adherence legal requirements fault risks receivables largely hedged internal group guidelines main focal points economic political risks continue functionality systems effectiveness internal carefully track credit countryspecific risks controls prevention loss assets effi position respond negative changes timely man ciency structures processes corresponding adjust ner since risks regarded concrete ments optimisations initiated necessary management financial investment risks individual risks group pursues defensive investment strategy important risks boehringer ingelheim management financial assets reflected exposed presented separately broken orientation portfolio focused european following specific categories financial risks legal economic monetary union emu government bonds risks production environmental risks personnel risks top credit ratings shortterm investments se sectorspecific risks lected banks results concrete risk risks identified concrete legal risks appear controllable means specific manage business activities group exposed legal ment procedures case risks regardless risks distinction made regulatory liability probability occurrence completely patent protection risks controlled even means targeted management proce dures term abstract used regulatory risks boehringer ingelheim exposed risks arising le financial risks gal disputes proceedings well official investiga relevant financial risks broken tions legal administrative decisions ongoing follows currency risks credit countryspecific risks future proceedings predicted regard plus management financial investment risks resultant risks abstract currency risks liability risks global orientation business activities results marketing sale pharmaceuticals exposed currency risks due exchange rate volatility group potential product liability risk boehringer ingelheim boehringer ingelheim annual report group management report currently product liability insurance compa risks area environment health safety nys risk profile absolutely guarantee howev ehs minimised preventively adherence er insurance coverage maintained rea extremely high safety standards appropriate emer sonable cost acceptable conditions gency plans drawn possible incidents sufficient protect boehringer ingelheim claim kind practised subjected comprehen loss potential claims losses sive quality testing regular intervals product liability claims could tie substantial fi nancial resources management capacity detri personnel risks mental companys image event boehringer ingelheim companies exposed market considers product unsafe ineffective demographic change resultant risk af result side effects regard risk abstract fected lack appropriately qualified personnel risk substantial impact companys busi patent protection risks ness activities therefore risk included protection innovations trademark brand longterm planning process many years patent rights particular importance boehringer acquired strategic significance result counter ingelheim research company commercial pro risk means comprehensive personnel concept tective rights increasingly target attacks regardless ethnic background gender religion breaches taken necessary precautions al offer company employees development opportuni low us detect threats early stage com ties based vocational skills social competence mencing appropriate countermeasures defend legal personal aptitudes willingness take responsibil position using legal means available us ity accordance needs company view risks regarded concrete countermeasures described risk garded concrete production environmental risks result fdas concern quality control sectorspecific risks ingelheim production facility following inspec boehringer ingelheim exposed business risks specific tions conducted last five years without complaint pharmaceutical industry risks change importance risk increased group significantly compared previous year contin result classified abstract ue regarded abstract addition loss ex clusivity products established market risks current focus attention effects fda associated development registration new warning letter dated may fda identified products risks increasingly include changing problems relating compliance cgmp standards restrictive requirements relating pricing reimburse ingelheim production facility warning letter ment many sales markets frequently prices ferred part foreign particles identified pharmaceutical products subject state batches containing active pharmaceutical ingredi monitoring regulation also price pressure ent api boehringer ingelheim taking matter cheaper generic drugs caused state reimbursement seriously working closely fda systems reason boehringer ingelheim monitors preparation comprehensive action programme various changes taking place sales mar deal fda concerns kets closely risk report report expected developments overall statement risk situation wellfilled product pipeline promising study todays perspective aware risks outcomes products development well sig alone conjunction risks could lead nificant sales potential justifies high investments impairment companys assets financial position rd plan invest research devel earnings could jeopardise continued exist opment new pharmaceutical products similar lev ence boehringer ingelheim el year review financial year continue renew report expected product portfolio process initiated developments entry therapeutic area oncology following marketing authorisation giotrif increase activities field diabetes based treatment financial year difficult one boehringer empagliflozin treatment respiratory diseases ingelheim nevertheless basically achieved olodaterol possible growth generated prod set achieve looking ahead remain ucts expected offset decline sales resulting schedule launch submission new prod loss exclusive rights products marketed ucts result measures taken reduce costs company lead growth medium term enhance efficiency also established strong starting point coming years view many challenges pharmaceutical sector currently faces strong growth expected next positive development year review years financial year expect see primarily attributable new blockbuster product sales company level pradaxa dabigatran etexilate indication stroke prevention patients atrial fibrillation net earnings one hand characterised products spiriva micardis sales satisfactory operating income generated adjusted currency effects increased businesses despite increase quality control meas ures ingelheim site following fda warning let ter also significantly affected particular furthermore trajenta linagliptin treatment special effects resulting closure ben venue type diabetes also offers significant sales potential laboratories ohio usa marketed part strategic alliance boehringer ingelheim eli lilly longterm collab ingelheim launch facility made progress oration joint development marketing diabe analysis restructuring procedures pro tes active ingredients also comprises active ingredi cesses next fda inspection expect ents ready market next years time first quarter important one work follows however continue una increased rd expenses thereby bated ensure longterm success correspond underlining strategic approach driving growth ing expenditure also anticipated area product supply primarily products research development investing major challenges thus associated higher ex good judgement intensive investigation penditure product registration making increas therapeutic benefit associated prospects success ingly difficult achieve higher prices innovative boehringer ingelheim annual report group management report drugs justify high investment costs corporate risks research development legislative interven tion pricing prescription medicines negative impact various markets overall despite circumstances described plan achieve operating income slightly level last year boehringer ingelheims declared aim remains continue develop company competitively successfully independent familyowned enterprise us long term sustainable organic growth still takes prece dence shortterm profit targets therefore confident great innovative strength based wellfilled pipeline global presence support highly qualified motivated employees key factor success achieve ambitious targets also continue stand vision value innovation researching developing innova tions offer high medical benefits bringing market aim endeavours make new drugs available enable doctors treat patients effectively currently possible consolidated financial statements boehringer ingelheim annual report consolidated financial statements consolidated financial statements overview major consolidated companies consolidated balance sheet consolidated profit loss statement cash flow statement statement changes group equity notes consolidated financial tatements auditors report overview major consolidated companies oovveerrvviieeww ooff tthhee mmaajjoorr ccoonnssoolliiddaatteedd ccoommppaanniieess c h boehringer sohn ag co kg boehringer ingelheim boehringer ingelheim boehringer ingelheim gmbh europe gmbh international gmbh germany p r austria p r austria r boehringer ingelheim boehringer ingelheim rcv forschungsinstitut fr molekulare pharma gmbh co kg gmbh co kg vienna pathologie gesellschaft mbh ingelheim boehringer ingelheim vienna boehringer ingelheim pharma gesmbh vienna vetmedica gmbh ingelheim belgium boehringer ingelheim czech republic scs boehringer ingelheim microparts gmbh dortmund boehringer ingelheim sro comm v brussels boehringer ingelheim prague biopharmaceuticals gmbh ingelheim china p finland boehringer ingelheim boehringer ingelheim international trading shanghai finland ky espoo co ltd shanghai norway philippines boehringer ingelheim boehringer ingelheim norway ks asker phil inc manila poland boehringer ingelheim spzoo warsaw distribution p production r research development sole personally liable managing shareholder boehringer ag boehringer ingelheim annual report consolidated financial statements c h boehringer sohn grundstcksverwaltung gmbh co kg boehringer ingelheim auslandsbeteiligungs gmbh argentina r ecuador netherlands p taiwan boehringer ingelheim sa boehringer ingelheim del ecuador boehringer ingelheim bv boehringer ingelheim buenos aires cia ltda quito alkmaar taiwan ltd taipei boehringer ingelheim animal health operations bv australia france p thailand alkmaar boehringer ingelheim pty ltd boehringer ingelheim boehringer ingelheim north ryde france sas paris thai ltd bangkok new zealand boehringer ingelheim brazil p greece p turkey nz ltd auckland boehringer ingelheim brasil boehringer ingelheim ellas ae boehringer ingelheim ilac quimica e farmaceutica ltda athens ticaret istanbul paulo portugal solana agro pecuaria ltda boehringer ingelheim lda indonesia p united kingdom arapongas lisbon pt boehringer ingelheim unilfarma lda lisbon boehringer ingelheim ltd indonesia jakarta bracknell canada boehringer ingelheim south africa italy p r usa p r canada ltd burlington boehringer ingelheim pty ltd boehringer ingelheim randburg boehringer ingelheim corp italia spa reggello ridgefield connecticut chile ingelheim pharmaceuticals pty ltd bidachem spa randburg boehringer ingelheim boehringer ingelheim ltda fornovo giovanni pharmaceuticals inc santiago de chile ridgefield connecticut japan p r south korea boehringer ingelheim china v p nippon boehringer ingelheim boehringer ingelheim usa corporation co ltd tokyo korea ltd seoul ridgefield connecticut boehringer ingelheim shanghai roxane laboratories inc ssp co ltd tokyo pharmaceuticals co ltd shanghai columbus ohio boehringer ingelheim china boehringer ingelheim spain p boehringer ingelheim investment co ltd shanghai vetmedica japan co ltd boehringer ingelheim vetmedica inc tokyo boehringer ingelheim vetmedica espaa sa barcelona st joseph missouri china investment co ltd shanghai boehringer ingelheim boehringer ingelheim sa boehringer ingelheim seiyaku co ltd yamagata boehringer ingelheim animal health barcelona roxane inc columbus ohio operations china co ltd taizhou boehringer ingelheim europharma sa barcelona boehringer ingelheim japan inc tokyo chemicals inc laboratorios fher sa barcelona petersburg virginia columbia p mexico p r boehringer ingelheim boehringer ingelheim sa sweden fremont inc bogot boehringer ingelheim fremont california promeco sa de cv boehringer ingelheim ab mexico city stockholm denmark p boehringer ingelheim vetmedica venezuela v boehringer ingelheim sa de cv guadalajara switzerland boehringer ingelheim ca danmark copenhagen caracas boehringer ingelheim schweiz gmbh basel pharmaton sa lugano consolidated financial statements c h boehringer sohn ag co kg ingelheim consolidated balance sheet assets millions eur notes intangible assets tangible assets financial assets fixed assets inventories accounts receivable assets securities cash cash equivalents current assets deferred charges prepaid expenses deferred taxes total assets liabilities equity millions eur notes shareholders capital group reserves balance sheet currency conversion difference net income equity minority interests group equity negative difference acquisition companies provisions accounts payable liabilities deferred charges deferred taxes total liabilities equity explanation see relevant section notes consolidated financial statements boehringer ingelheim annual report consolidated financial statements c h boehringer sohn ag co kg ingelheim consolidated profit loss statement millions eur notes net sales changes inventories internal work performed capitalised operating income total revenues material costs personnel costs amortisation intangible depreciation tangible assets operating expenses operating income financial income holding income income taxes taxes income taxes thirdparty share net income explanation see relevant section notes consolidated financial statements due legal requirements disclosure shareholders personal taxes arising consolidated business activities tax expenses allowed taxes shown withdrawals accrued group capital items consolidated profit loss statement show value due rounding millions eur disclosed consolidated financial statements c h boehringer sohn ag co kg ingelheim cash flow statement millions eur income taxes including thirdparty share writedownswriteups fixed assets change provisions pensions cash flow change provisions noncash income expenses loss disposals fixed assets change inventories change accounts receivable assets related investing financing activities change trade accounts payable liabilities related investing financing activities cash flow operating activities investments intangible assets investments property plant equipment investments noncurrent financial assets proceeds disposals tangible assets proceeds disposals noncurrent financial assets cash flow investing activities cash receipts fromcash payment owners minority shareholders cash proceeds borrowingsrepayments loans cash flow financing activities change liquid funds cash relevant transactions changes liquid funds due exchange rate movements financial funds financial funds excl fixedasset securities liquid funds securities within fixed current assets source funds use funds boehringer ingelheim annual report consolidated financial statements c h boehringer sohn ag co kg ingelheim statement changes group equity thereof thereof shareholders accrued currency minority currency millions eur capital group capital effects equity interests effects group equity balance withdrawals net income changes balance withdrawals net income changes balance shareholders capital consists equity c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg capital consists limited partners capital contribution shareholders personal taxes arising consolidated business activities shown withdrawals accrued group capital items statement changes equity show value due rounding millions eur disclosed notes consolidated financial statements c h boehringer sohn ag co kg ingelheim notes consolidated financial statements principles methods general principles consolidated financial statements boehringer ingelheim financial year prepared accordance section handelsgesetzbuch hgb german commercial code line requirements group accounting sections et seq hgb accordance section paragraph hgb consolidated financial statements consist con solidated balance sheet consolidated profit loss statement notes consolidated financial statements cash flow statement statement changes equity consolidated financial statements prepared euro accordance section paragraph conjunction section hgb improve clarity consolidated financial statements individual items consolidated balance sheet consolidated profit loss statement combined items presented ex plained separately notes additional disclosures required individual items also found notes information companies included consolidation parent company boehringer ingelheim group c h boehringer sohn ag co kg ingelheim boehringer ag ingelheim sole personally liable managing shareholder company besides c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg general partner controlled c h boehringer sohn ag co kg boehringer ingelheim group consists total affiliated companies germany abroad addition c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg companies c h boehringer sohn ag co kg directly indirectly holds majority voting rights fully consolidated consolidated financial statements companies included consolidation accordance section paragraph hgb reporting year individually collectively insignificant net assets financial position results operations group total amount sales equity net income companies included consolidation account less aggregated group financial statements totals companies also classified associates accordance section paragraph hgb account immateriality ongoing restrictions disposal two companies account boehringer ingelheim annual report consolidated financial statements articles association included consolidation accordance section para graph sentence hgb total number affiliated companies increased two previous year one company sold two companies founded one company acquired following subsidiaries exempted reporting disclosure obligations section para graph hgb boehringer ingelheim gmbh ingelheim boehringer ingelheim europe gmbh ingelheim boehringer ingelheim vetmedica gmbh ingelheim boehringer ingelheim secura versicherungsvermittlungs gmbh ingelheim boehringer ingelheim grundstcksgesellschaft mbh ingelheim boehringer ingelheim finanzierungs gmbh ingelheim boehringer ingelheim rd beteiligungs gmbh ingelheim boehringer ingelheim venture fund gmbh ingelheim exempt duty prepare disclose annual financial statements management reports ac cordance hgb provisions corporations section b hgb c h boehringer sohn ag co kg ingelheim c h boehringer sohn grundstcksverwaltung gmbh co kg ingelheim boehringer ingelheim pharma gmbh co kg ingelheim c h boehringer selbstmedikation kg ingelheim boehringer ingelheim veterinary research center gmbh co kg hanover consolidation methods inventories fixed assets receivables liabilities income expense items transactions companies included consolidation eliminated part debt consolidation accordance section hgb elimination intercompany profits accordance section hgb con solidation income expenses accordance section hgb revaluation method section hgb applied acquisition accounting firsttime consolida tion subsidiaries firsttime consolidation occurred date company became subsidiary carrying amount shares held parent company offset corresponding equity subsidiary equity carried amount fair value assets liabilities prepaid expenses deferred income special reserves included consolidated financial statements time con solidation remaining balance offsetting capitalised goodwill notes consolidated financial statements currency translation assets liabilities resulting foreign currency transactions translated using middle spot ex change rate balance sheet date realisation principle section paragraph conjunction section paragraph nd halfsentence hgb historical cost convention section paragraph conjunction section paragraph sentence hgb complied remain ing terms one year consolidated financial statements financial statements foreign subsidiaries domiciled state outside euro zone denominated foreign currency converted euro accord ance section hgb using modified closing rate method using modified closing date rate method asset equity liability items annual financial state ments prepared foreign currency translated euro using middle spot exchange rate closing date exception equity translated using historical rate items profit loss statement translated euro using average rate resulting translation difference reported within consolidated equity reserves within difference equity currency transla tion important currencies group developed follows reporting year basis eur yearend rate average annual rate us dollar japanese yen pound sterling canadian dollar boehringer ingelheim annual report consolidated financial statements accounting policies fixed assets acquired intangible assets tangible assets carried cost less straightline amortisation deprecia tion respectively line technical economic circumstances based following useful lives intangible assets years buildings years technical equipment machinery years equipment operating office equipment years straightline depreciation amortisation used consolidated financial statements anticipated permanent impairment shown extraordinary writeoffs direct costs materials labour costs appropriate portions materials labour overheads depreciation fixed assets caused pro duction taken account determining production costs capitalised intangible assets limited useful life goodwill firsttime consolidation shares usually amortised period five years useful life ten years applied goodwill boehringer ingelheim korea ltd acquired past experience products sales markets business conditions boehringer ingelheim korea ltd shown presents true fair view financial assets essentially included shareholder rights securities loans carried lower cost fair market value impaired current assets prepaid expenses inventories carried lower cost fair market value raw materials consumables supplies capitalised lower average acquisition prices fair market value balance sheet date finished goods work progress measured production cost basis individual calcula tions taking account directly attributable costs materials direct labour costs special direct costs appropriate shares production materials overheads depreciation goods resale valued lower either purchase cost fair market value identifiable risks inventory assets arising aboveaverage storage periods diminished marketability lower replacement costs taken account appropriate valuation adjustments notes consolidated financial statements inventories valued lossfree ie discounts recognised expected sales prices costs yet incurred receivables assets recognised cost less allowances specific risks general credit risk lowinterest noninterestbearing receivables term one year discounted securities classified current assets include securities recognised lower cost quotedmarket prices reporting date cash cash equivalents recognised lower cost fair market value deferred charges prepaid expenses accordance section paragraph hgb include expenses paid advance certain period balance sheet date deferred charges accordance section paragraph hgb include proceeds income certain period balance sheet date negative difference acquisition companies negative difference acquisition companies recognised result net assets two companies acquired march august exceeding purchase price value negative difference acquisition companies amounting eur million january creased acquisition company acquired august amounting eur million lease negative difference acquisition companies eur million financial year eur million shown operating income amount release negative difference acquisition companies line amortisation excess net assets time acqui sition period amortisation currently estimated ten years group reserves group reserves include retained earnings consolidated subsidiaries prior years consolida tion entries affect earnings related prior years provisions tax provisions provisions include uncertain liabilities expected losses executory con tracts carried amount required settle obligation based reasonable business judge ment accordance prudence principle ie including future cost price increases provisions remaining term one year discounted using matchedterm average market interest rate last seven years accordance rckstellungsabzinsungsverordnung german regula tion discounting provisions boehringer ingelheim annual report consolidated financial statements liabilities liabilities recognised settlement amount deferred taxes calculate deferred taxes temporary quasipermanent differences accounting carrying amounts assets liabilities prepaid expenses deferred income tax carrying amounts tax loss carryforwards amounts resulting tax benefits expenses time reversal measured using tax rates specific respective consolidated company discounted dif ferences due consolidation measures accordance sections hgb also measured us ing companyspecific tax rates time expected reversal difference deferred tax assets loss carryforwards taken account likely used within next five years deferred tax assets liabilities reported without netted notes consolidated financial statements notes consolidated balance sheet intangible assets acquired goodwill advance total concessions payments millions eur similar rights procurementmanufacturing costs balance currency conversion difference additions due first consolidation additions disposals reclassifications balance currency conversion difference additions due first consolidation additions disposals reclassifications balance accumulated depreciation balance currency conversion difference additions due first consolidation additions writeups disposals reclassifications balance currency conversion difference additions due first consolidation additions writeups disposals reclassifications balance book value book value boehringer ingelheim annual report consolidated financial statements tangible assets land technical advance total buildings facilities facilities payments machines operating construction millions eur equipment progress procurementmanufacturing costs balance currency conversion difference additions due first consolidation additions disposals reclassifications balance currency conversion difference additions due first consolidation additions disposals reclassifications balance accumulated depreciation balance currency conversion difference additions due first consolidation additions writeups disposals reclassifications balance currency conversion difference additions due first consolidation additions writeups disposals reclassifications balance book value book value notes consolidated financial statements financial assets investments loans investments investment total affiliated affiliated related securities loans millions eur companies companies companies procurementmanufacturing costs balance currency conversion difference additions due first consolidation additions disposals reclassifications balance currency conversion difference additions due first consolidation additions disposals reclassifications balance accumulated amortisation balance currency conversion difference additions due first consolidation additions writeups disposals reclassifications balance currency conversion difference additions due first consolidation additions writeups disposals reclassifications balance book value book value previous year loans item include loans shareholders boehringer ingelheim annual report consolidated financial statements inventories millions eur raw materials supplies unfinished products finished products goods resale advance payments suppliers accounts receivable assets residual residual term term millions eur year year trade accounts receivable receivables affiliated companies receivables related companies assets assets item includes receivables shareholders eur million previous year eur million receivables affiliated companies previous year almost exclusively consist receivables loans receivables related companies essentially consist trade accounts receivable provisions millions eur pension provisions tax provisions provisions notes consolidated financial statements provisions pensions similar obligations provisions pensions similar obligations determined basis actuarial calculations using projected unit credit method taking account future adjustments salaries pensions addition local biometric data eg prof heubecks g mortality tables germany pension obliga tions significant countries calculated basis following actuarial parameters december germany usa japan discount rate salary increase pension increase provisions pensions similar obligations discounted using average market interest rate remaining term years accordance german regulation discounting provisions november interest rates used discount significant foreign pension obligations us japan determined comparable parameters line german regulation discounting provisions november plan assets intended solely cover pension similar obligations unavailable credi tors cover assets within meaning section paragraph sentence hgb measured fair mar ket value essentially derived stock market prices offset underlying pension similar obligations fair market value plan assets balance sheet date eur million corresponding present value pension similar obligations eur million gains losses plan assets interest expense relating pension similar obligations offset accord ance section paragraph sentence hgb total eur million gains plan assets eur million interest expense relating pension similar obligations included financial income boehringer ingelheim annual report consolidated financial statements accounts payable residual term residual term less less millions eur year years years year bank loans accounts payable trade accounts payable advance payments accounts payable affiliated companies accounts payable related companies liabilities taxes eur million social security liabilities eur million previous year liabilities secured mortgages similar collateral rights balance sheet date end year liabilities shareholders eur million previous year eur million payables affiliated companies consist payables loans amounting eur million previous year eur million trade accounts payable amounting eur million previous year eur million notes consolidated financial statements notes consolidated profit loss statement structure consolidated profit loss statement based total cost format net sales business business segment millions eur prescription medicines consumer health care animal health biopharmaceuticals industrial customers sales geographic region millions eur europe germany americas usa asia australia africa japan operating income operating income includes income currency translation eur million previous year eur million material costs millions eur costs raw material supplies goods resale expenditure services boehringer ingelheim annual report consolidated financial statements personnel costs millions eur salaries wages social benefits retirement benefits retirement benefits interest effects measurement provision pensions similar obligations shown separate item financial income average headcount production administration marketing sales research development apprentices amortisation intangible assets depreciation tangible assets amortisation intangible fixed wassets depreciation fixed tangible assets include extraordinary writedowns eur million previous year eur million operating expenses operating expenses include expenses currency translation eur million previous year eur million operating expenses essentially include thirdparty services areas research development med icine marketing plus administrative expenses fees contributions commissions rent freight ex penses thirdparty repairs notes consolidated financial statements financial income millions eur interest expense relating pensions similar obligations provisions interest expense similar expenditure interest expense similar expenditure amortisation loss disposal financial assets shortterm investments income investment securities longterm loans interest income similar proceeds holding income millions eur writeoffs financial assets income related companies affiliated companies taxes millions eur income taxes deferred taxes current income taxes essentially include costs corporation trade tax companies included consolidation result conclusion profit transfer agreements significant german corporations cluded trade corporation tax group parent company c h boehringer sohn ag co kg since january income taxes shareholders c h boehringer sohn ag co kg curred operating income reported consolidated profit loss statement trade income tax companies concerned fully consolidated german partnerships shown tax expenses total deferred tax assets amounted eur million balance sheet date deferred tax assets essentially relate different carrying amounts provisions fixed assets inventories deferred tax liabilities recognised amount eur million mainly relate differences car rying amounts tangible assets inventories provisions boehringer ingelheim annual report consolidated financial statements net income net income positively influenced priorperiod operating income essentially versal provisions eur million previous year eur million negatively influenced priorperiod operating expenses eur million previous year eur million notes cash flow statement cash flow statement shows cash cash equivalents cash longterm securities invest ments classified current assets sold time boehringer ingelheim group changed result cash inflows outflows reporting year accordance german accounting standard cash flow statement gas broken according cash flows operating activities cash flows investing financing activities changes balance sheet items affiliated companies included translated using average rates year balance sheet cash cash equivalents carried closing rate effect exchange rate changes cash cash equivalents shown separately financial year eur million received interests eur million previous year eur mil lion paid interests eur million previous year eur million paid taxes notes consolidated financial statements disclosures contingent liabilities eur million liabilities guarantees bills cheque guarantees warranties granting security thirdparty liabilities risk utilisation individual contingent liabilities estimated follows risk utilisation guarantees liabilities banks affiliated companies rated low ac count solid net assets financial position results operations subsidiaries question financial commitments millions eur rental leasing obligations purchase commitment obligations rental lease agreements eur million previous year eur million eur million previous year eur million relating longterm rental agreements sub sidiaries included consolidation purpose lease agreements lower capital commitment compared buying property absence resale risk risks could arise term lease longer possible fully utilise properties indications time financial commitments include future expenses followup investments investments already ini tiated future major repairs balance sheet date purchase commitments include future cash vestments eur million previous year eur million offbalance sheet transactions derivative financial instruments hedges owing extensive international structure boehringer ingelheim group highly dependent de velopments worlds currencies interest rates hedge risks particularly emerging goods services financing currency forwards options generally used currency risks interest rate swaps options used interest rate risks use derivative financial instruments organisational processes set internal guide lines strict separation trading processing documentation control risk positions regularly tracked analysed measured special consolidated financial report positions entered periodically reevaluated monitored fair market values derivative boehringer ingelheim annual report consolidated financial statements financial instruments calculated using standard market measurement methods currency interest forwards using net present value method currency interest options using recognised option pricing models basis market data available balance sheet date currency interest options recognised fair market value exceeding option premium paid received derecognised maturity provisions eur million recognised currency forwards included hedge accounting negative fair market value within currency balance sheet date line imparity principle positive fair market values within currency recognised balance sheet date following derivative financial instruments included hedge accounting nominal value market value millions eur foreign exchange forward contracts requirements hedge accounting foreign exchange forward contracts highly probable fore casted transactions accordance section hgb met foreign exchange forward contracts recognised balance sheet line net hedge presentation method following accounting policies apply recognition hedges accordance section hgb economic hedges accounted hedge accounting hedges recognised per foreign currency net amount highly probable forecasted transactions currency forwards match forecasted net cash flow terms maturity nominal amount foreign currency macro hedge highly probable forecasted transactions incoming outgoing payments planned sales purchases derived company planning expost analysis planning shown planned transactions highly probable critical terms maturity nominal amount foreign currency match opposing changes value hedged item hedging instrument fully offset effective hedge therefore assumed prospectively retrospectively critical term match method exclusively used measure pro spective retrospective hedge effectiveness notes consolidated financial statements december hedges highly probable forecast net cash flows recognised follows january december net cash flow millions eur fx forward contracts millions eur nominal value nominal value market value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn gbp gbp gbp january december net cash flow millions eur fx forward contracts millions eur nominal value nominal value market value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn gbp gbp gbp january december net cash flow millions eur fx forward contracts millions eur nominal value nominal value market value usd usd usd jpy jpy jpy january may net cash flow millions eur fx forward contracts millions eur nominal value nominal value market value jpy jpy jpy boehringer ingelheim annual report consolidated financial statements amount hedged foreign currency risk correlates relative change exchange rate planning date realisation date forecasted transactions currencies appreciate depreciate euro would foreign currency risk plus minus eur million without hedging balance sheet date two floatingrate loans amounting eur million interest rate swaps matching amounts matching maturities concluded hedge interest rate risk associated involves transforming floatingrate loan portions fixed interest rate use made hedge accounting micro hedges opposing changes value hedged item hedging instrument fully offset balance sheet date interest rate swaps including accrued interest fair market value minus eur million carrying amount equal deferred accrued interest eur million reported liabilities banks net hedge presentation method used research development expenses millions eur research development expenses research development expenses capitalised include costs phase iv clinical studies total auditor fees total fee charged auditor financial year eur million eur million relates audits financial statements eur million assurance valuation services eur million services auditors report auditors report audited consolidated financial state conducted audit consolidated finan ments prepared ch boehringer sohn ag cial statements accordance article co kg ingelheim comprising balance sheet hgb german commercial code german income statement statement changes eq generally accepted standards audit fi uity cash flow statement notes con nancial statements promulgated institut der solidated financial statements together wirtschaftsprfer institute public auditors group management report business year germany idw standards require january december prepa plan perform audit misstate ration consolidated financial statements ments materially affecting presentation group management report accordance net assets financial position results opera german commercial law responsibility tions consolidated financial statements managing directors managing cor accordance german principles proper ac porate general partner responsibility counting group management report express opinion consolidated financial detected reasonable assurance knowledge statements group management report business activities economic legal based audit environment group expectations possible misstatements taken account determination audit procedures effec tiveness accountingrelated internal control system evidence supporting disclo sures consolidated financial statements group management report examined pri marily test basis within framework audit audit includes assessing annual fi nancial statements companies included consolidation determination companies included consolidation accounting consolidation principles used significant estimates made managing directors managing corporate general partner well evaluating overall presentation consoli dated financial statements group manage ment report believe audit provides reasonable basis opinion boehringer ingelheim annual report consolidated financial statements exception following qualification audit led reservations contrary article nos b hgb total remuneration granted members former members board managing directors members supervisory body well pension provisions recognized recognized former members board managing directors disclosed notes con solidated financial statements opinion based findings audit qualification mentioned con solidated financial statements comply legal requirements consolidated financial state ments give true fair view net assets financial position results operations group accordance german principles proper accounting group management report consistent consolidated financial statements comply legal requirements whole provides suitable view groups position suitably presents opportunities risks future development frankfurt main february pricewaterhousecoopers aktiengesellschaft wirtschaftsprfungsgesellschaft philip marshall dr ulrich strk wirtschaftsprfer wirtschaftsprfer german certified german certified public accountant public accountant product portfolio boehringer ingelheim annual report product portfolio product portfolio selection branded prescription medicines consumer health care animal health branded prescription medicines respiratory diseases chronic obstructive pulmonary disease copd bronchial asthma bronchial asthma among prevalent bronchial asthma chronic inflammatory disor chronic diseases affecting lungs frequent der airways chronic inflammation air cause morbidity premature deaths worldwide ways accompanied airway hyperresponsive ness leads narrowing airways copd recurrent episodes wheezing breathlessness copd chronic disease lungs coughing particularly night early hours airways become narrowed leads limitation morning known asthma airflow causing shortness breath res triggered genetic environmental factors piratory symptoms airflow limitation e g allergens viral infections quite variable partially reversible usually worsens gradually breathing difficulties may occur early stages time destruction lung tissue mainly affect disease airflow limitation normally ful ing alveoli thus gas exchange excessive ly reversible patients free symptoms mucus airways inducing chronic cough con attacks contrast copd asthma tribute burden disease complaints occur childhood main reasons copd stressful patients lung emphysema chronic bronchitis main manifestations copd copd caused continuous damage lungs resulting inhaling pollutants primarily ciga rette smoke also environmental pollutants air irritants lungs course copd disease occurs second half humans life characterised acceler ated loss lung function compared normal age ing occasional sudden worsening symptoms function referred acute exacerbations boehringer ingelheim annual report product portfolio indications brand names active ingredients chronic obstructive spiriva tiotropium bromide maintenance treatment patients pulmonary disease copd forvent copd chronic obstructive pulmonary disease including chronic bronchitis emphysema maintenance treatment associated dyspnoea prevention exacerbations chronic obstructive striverdi olodaterol maintenance bronchodilator treatment pulmonary disease copd patients chronic obstructive pulmonary disease copd bronchospasms associated combivent ipratropium bromide management reversible broncho reversible obstructive salbutamol spasms associated obstructive airway diseases airway diseases patients requiring one bronchodilator chronic obstructive atrovent ipratropium bromide bronchodilator maintenance treat pulmonary disease copd ment bronchospasms associated chronic bronchitis chronic obstructive pulmonary disease asthma copd including chronic bronchitis emphysema asthma bronchial asthma berodual ipratropium prevention treatment symptoms chronic bronchitis bronchodual bromide chronic obstructive airway disorders duovent fenoterol reversible airflow limitations bronchial asthma especially chronic bronchitis without em physema bronchial asthma berotec fenoterol symptomatic treatment acute asthma attacks conditions versible airway narrowing e g chronic obstructive bronchitis prophylaxis exerciseinduced asthma bronchial asthma inflammide budesonide chronic control symptoms bron chial asthma bronchial asthma alesion epinastine prophylactic treatment bronchial allergic rhinitis flurinol asthma prophylaxis symptomatic treatment allergic rhinitis branded prescription medicines cardiovascular diseases cardiovascular diseases leading causes acute myocardial infarction death many countries still increasing acute myocardial infarction heart attack prevalence acute event occurs thrombus clot suddenly prevents blood flow area heart stroke muscle unless blood flow restored quickly stroke rapidly developing loss brain af fected section heart muscle becomes perma functions due blockage blood flow nently damaged heart attack leading cause affected brain tissue due ischaemia death developed countries lack blood supply caused thrombosis embolism due bleeding result affected area brain unable function damage quickly becomes permanent untreated stroke acute event requiring emergency diagnosis intervention worldwide stroke one leading causes death longterm disability symptoms transient ischaemic attack tia similar stroke last minutes hours tia may precede stroke emergency medical care subsequent preventive treatment necessary boehringer ingelheim annual report product portfolio indications brand names active ingredients essential hypertension micardis telmisartan treatment essential hypertension cardiovascular prevention micardisplus telmisartan hydrochlorothiazide reduction risk myocar micardis plus dial infarction heart attack stroke micardis hct death cardiovascular cv causes comicardis patients years age older high risk developing major cv events unable take ace inhibitors usa reduction cardiovascular mor bidity patients manifest athero thrombotic cardiovascular disease tory coronary heart disease stroke peripheral arterial disease type diabetes mellitus documented tar get organ damage eu hypertension twynsta telmisartan amlodipine treatment hypertension alone micamlo antihypertensive agents initial micardis amlo therapy patients likely need multi micardis anlo ple antihypertensive agents achieve micardis duo blood pressure goals usa micardis duo addon therapy adult patients adequately controlled blood pressure amlodipine replacement therapy adult patients receiving telmisartan amlodipine separate tablets eu secondary prevention aggrenox dipyridamole prevention stroke following first stroke transient ischaemic agrenox acetylsalicylic acid stroke transient ischaemic attacks attacks tia asasantin asasantin retard hypertension catapresan clonidine forms high blood pressure unless catapres caused phaeochromocytoma catapressan acute ischaemic stroke actilyse alteplase fibrinolytic treatment acute ischae acute myocardial infarction actilyse cathflo mg mic stroke acute myocardial infarction acute massive pulmonary acute massive pulmonary embolism embolism catheter clearance due thrombotic catheter clearance due occlusion thrombotic occlusion branded prescription medicines cardiovascular diseases continued hypertension cardiovascular diseases atrial fibrillation hypertension also referred high blood pressure patients atrial fibrillation af higher risk chronic disease blood pressure developing blood clots cause disa chronically elevated hypertension one bling stroke clots travel brain af jor risk factors strokes heart attacks heart failure common type arrhythmia associated chronic renal failure hypercoagulable state predisposes stroke systemic embolism prevented one billion people worldwide affected effective chronic anticoagulation hypertension prevalence essential hyperten sion increases steadily age world popu venous thromboembolism lation ageing preventive strategies terms patients undergoing orthopaedic surgery con lifestyle changes far failing prevalence siderable risk developing deep vein thrombosis hypertension set increase even legs potentially fatal pulmonary embolism also known venous thromboembolism hypertension major risk factor cardiovascular vte longer term thromboembolic events morbidity mortality organs risk pri may recur chronic venous insufficiency andor marily heart main blood vessels brain pulmonary hypertension may occur prevent vte kidneys primary goal antihyper events consequences patients receive tensive treatment prevent cardiovascular events kind thromboprophy laxis heart attacks strokes finally reduce cardiovascular mortality cardiovascular disease cvd responsible nearly one three deaths worldwide number one cause death proper control treatable risk factors disease vital prevention cardiovascular events boehringer ingelheim annual report product portfolio indications brand names active ingredients acute myocardial infarction metalyse tenecteplase fibrinolytic treatment acute myocar dial infarction hypertension motens lacidipine treatment essential hypertension stroke prevention atrial pradaxa dabigatran prevention strokes blood clots fibrillation pradaxar etexilate patients abnormal heart rhythm prazaxa atrial fibrillation primary prevention venous pradaxa dabigatran primary prevention venous thrombo thromboembolic events pradaxar etexilate embolic events vte adults orthopaedic surgery elective total hip knee replacement surgery prescription medicines metabolic diseases diabetes estimated number cases reach type diabetes chronic progressive condition million cause longterm complications well controlled longterm complications diabetes include ne phropathy leading renal failure potential every year million deaths worldwide linked risk dialysis retinopathy potential loss vi directly longterm effects diabetes type sion increased incidence stroke cardiovas diabetes common form accounts cular diseases peripheral neuropathy risk cases developed world foot ulcers foot leg amputations auto affects million people worldwide imposing nomic neuropathy causing gastrointestinal genitouri enormous burden health care systems globally nary cardiovascular symptoms sexual dys without effective prevention management function oncology cancer threat global health esti lung cancer one disease mated million new cases cancer diag different subtypes small cell lung cancer nosed worldwide million people died sclc nonsmall cell lung cancer nsclc malignant disease common newly different molecular genetic aberrations diagnosed cancer types lung cancer mutations present tumour identi breast cancer colorectal cancer fied focusing molecular changes spe cific specific subtype lung cancer targeted lung cancer therapies may effective treat lung cancer bronchogenic carcinoma refers ments less harmful normal cells thereby malignant abnormal cell growth inside lung tis reducing side effects normal cells sue forming cluster tumour com mon cancer estimated million new cases mutations egf receptor epidermal growth per year worldwide smoking primary factor receptor egfr erbb occur cause disease contributing cas caucasians around asian patients es recently incidence lung cancer among adenocarcinoma type mutation oc nonsmokers women increased lung cancer curs frequently exclusively women negative prognosis million deaths per nonsmokers treated tyrosine year representing cancer deaths lung kinase inhibitors tkis erbb blockers cancer signs unspecific may take many years receptor family giotrifgilotrif afatinib appear late diagnosis advanced stage disease results negative prognosis lung cancer patients surviving five years following diagnosis boehringer ingelheim annual report product portfolio indications brand names active ingredients type diabetes mellitus trajenta linagliptin treatment type diabetes mellitus tradjenta improve glycaemic control adults trazenta used monotherapy metformin trayenta tolerated contraindicated combination therapy type diabetes mellitus jentadueto linagliptin metformin hydrochloride treatment type diabetes mellitus trayenta duo improve glycaemic control adults trajenta duo treatment metformin lead sufficient control patients treated trajenta metformin indications brand names active ingredients nonsmall cell lung cancer giotrif afatinib treatment patients meta nsclc gilotrif static nonsmall cell lung cancer nsclc whose tumors activating epidermal growth factor receptor egfr mutations branded prescription medicines diseases central nervous system mental neurological diseases depression primary symptoms r esult lack parkinsons disease significantly impact patients neurotransmitter dopamine distinct areas families substantial burden human brain society restless legs syndrome rls parkinsons disease restless legs syndrome rls common neurolog parkinsons disease pd degenerative disorder ical disorder characterised uncontrollable urge central nervous system patients usually move legs primarily occuring evening notice motor symptoms like hand tremor shaking night hours usually accompanied un first sign disease progresses even pleasant sometimes painful sensations tually include shaking arms legs head legs well disturbed sleep resulting daytime motor symptoms may develop time tiredness sleepiness sensations felt deep include stiffness often results loss facial within legs described creeping crawl expression gradual slowing loss motion ing aching freezing patients also suffer nonmotor symptoms associated pd dementia depression sleep disorders infectious diseases hiv infectionaids acquired immune deficiency syndrome aids set symptoms infections resulting damage human immune system caused human immunodeficiency virus hiv untreated condition progressively reduces effective ness immune system leaves individuals susceptible opportunistic infections tumours babies infected mothers risk getting virus pregnancy childbirth breastfeeding boehringer ingelheim annual report product portfolio indications brand names active ingredients parkinsons disease pd sifrol pramipexole symptomatic treatment idiopathic restless legs syndrome rls mirapex parkinsons disease may used mirapex er monotherapy combination mirapexin levodopa symptomatic treatment pexola idiopathic moderate severe restless legs syndrome sleep disorders lendormin brotizolam shortterm treatment disorders lindormin initiating maintaining sleep indications brand names active ingredients hivaids viramune nevirapine available tablets suspension viramune xr adults children combina tion therapy hiv infection several countries prevention mothertochild transmission hiv pregnant women taking antiretroviral therapy time labour prolonged release tablets oncedaily dosing within combination therapy hivaids aptivus tipranavir capsule oral solution coadminis tered mg ritonavir indi cated combination antiretroviral treatment hivinfected patients evidence viral replication treatment experienced infected hiv strains resistant one pro tease inhibitor consumer health care cough cold mucosolvan ambroxol bisolvon mucoviral bisolviral antiviral nasal sprays bromhexine indicated secretolytic launched sprays contain iota therapy broncho pulmonary diseases associated carrageenan extracted natural red sea abnormal mucus secretion impaired mucus weed applied nasally iotacarrageenan acts transport like protective layer inhibits infection nasal epithelial cells cold viruses since viruses cough common symptom clinical im dock specific receptors cell sur portance frequent reason consulting face clinical trials use mucoviralbisolviral doctor visiting pharmacy clinical symptoms shown reduce viral load pa cough expectoration led develop tients nasal secretion reduce duration ment drugs affect respiratory mucus e cold mucoactive agents boxagrippal launched germany mucosolvan promotes mucus clearance fa following successful switch prescription cilitates expectoration eases productive cough overthecounter otc medicine status cold allowing patients breathe freely deeply remedy combines antiinflammatory pain reliev available many different product forms er nsaid ibuprofen oral decongestant mulations pseudoephedrine hydrochloride treat troublesome symptoms cold blocked nose ambroxol active metabolite bromhexine sinuses combination headache fever synthetic derivative herbal coldrelated pain active ingredient vasicine extracted plant species adhatoda vasica ambroxol mucoactive drug several properties including secretolytic secretomotoric actions restore physio logical clearance mechanisms respiratory tract play important role bodys natural defence mechanisms ambroxol also stimu lates synthesis release surfactant type ii pneumocytes bisolvon available age groups market since bromhexine contained various formulations bisolvon shown increase proportion serious bronchi al secretion making easily expectorated bromhexine also enhances mucus transport ducing mucus viscosity activating ciliated epithelium boehringer ingelheim annual report product portfolio indications brand names active ingredients acute chronic broncho mucosolvan ambroxol secretolytic therapy acute chronic pulmonary diseases mucosan bronchopulmonary diseases associated surbronc abnormal mucus secretion im lasolvan paired mucus transport mucopect acute chronic broncho bisolvon bromhexine secretolytic therapy acute chronic pulmonary diseases bisolvon chesty bronchopulmonary diseases associated bisolvonlinctus abnormal mucus secretion im paired mucus transport irritable cough silomat dmp dextrometorphan symptomatic treatment irritable non bisoltussin productive cough bisolvon dry bisolsek bisolvon antitusivo common cold mucoviral iotacarrageenan antiviral treatment common cold bisolviral also used sustained moisturi surbroncviraltm sation nasal mucosa common cold boxagrippal ibuprofen symptomatic treatment nasal conges pseudoephedrine tion combination headache andor fever consumer health care sore throat mucoangin ambroxol indicated pain relief addition secretolytic activity ambroxol acute sore throat pain sore throat hall potent inhibitor neuronal sodium channels mark acute pharyngitis usually caused viral therefore mucoangin shown local anaes infection infection rule selflimited thetic effect described first late patient normally recovers couple days explained confirmed recent work bothersome patient con tinuous pain throat maximised swallowing main goal treatment thus reduce pain pain brand thomapyrin comprises products type headaches migraines thomapyrin posi treatment acute pain mild intermediate intensity tioned expert treatment headaches several line extensions available thomapyrin classic thomapyrin classic core product normal headache thomapyrin intensiv composed triple combination acetylsalicylic stronger headache thomapyrin effervescent acid paracetamol caffeine three components tablets galenic alter native suppress pain synergistically via interaction several painrelated molecular mechanisms alongside thomapyrin boehringer ingelheim also sult thomapyrin classic offers faster superior offers analgesics combination ibuprofen efficacy compared single components allylisopropylacetylurea dehydrated caffeine amongst others well proven stateoftheart magnesium oxide japan tradename clinical studies eve mono active ingredient metami zol brazil tradename anador reason triple combination recom mended many national international medical societies first choice acute treatment tension boehringer ingelheim annual report product portfolio indications brand names active ingredients sore throat mucoangin ambroxol pain relief acute sore throat lysopadol lysopain dol isodinemint zerinol gola indications brand names active ingredients pain thomapyrin acetylsalicylic acid adults adolescents older thomapyrin classic paracetamol caffeine years acute treatment mild thomapyrin intensiv moderate headache migraine attacks without aura treat ment tensiontype headache available germany pain eve ibuprofen adults older years reduc eve allylisopropylacetylurea dehydrated tion fever temporary relief mild eve quick caffeine magnesium oxide moderate aches pains associated headache menstrual pain oth er body pains available japan eve quick pain anador metamizol adults adolescents older lisalgil years acute treatment mild nolotil moderate headache available brazil consumer health care gastrointestinal diseases gastrointestinal portfolio offer several modic product buscopan acts directly site brands dulcolax surulac laxoberal abdominal pain relaxing smooth muscles guttalax buscopan well heartburn gastrointestinal biliary urinary genital tracts brands zantac buscopan antiacido gastol means buscopan relieves abdominal pain directly treating main cause abdominal cramp constipation common problem dulcolax spasm leading overthecounter otc laxative remedy constipation relief worldwide today buscopan available several line exten sions mono variant different combinations dulcolax tablets special enteric comfort analgesics paracetamol ibuprofen metam coating ensures active ingredient izoldipyrone different formulations tablets dulcolax tablets bisacodyl taken drops suppositories syrup solutions intrave needs act colon colon co nous injection lonic juices activate key ingredient relieves consti pation stimulates natural move umbrella brand buscopan also offers buscofem ment bowels provide gentle predictable menstrual pain relief well buscopan relief within hours one two tablets taken antiacido b uscopan reflusso heartburn going bed provide relief next relief morning extended gastrointestinal portfolio products within dulcolax range include vaprino new selfmedication product dulcoease dulcoenema dulcogas diarrhoea active ingredient racecadotril effective various forms acute diarrhoea surulac constipation brand japan reducing exceeding secretion gut without consumers offered surulac laxative tablet changing gastrointestinal transit time motility laxoberal guttalax brands offering vaprino provides new mode action consumers constipation relief flexible dosage enables fast relief diarrhoea without format namely drops blocking bowels abdominal cramping pain discomfort com mon ailments approximately one four persons worldwide suffers regular basis buscopan antispasmodic product active ingredient hyoscine butylbromide product basically natural substance extracted duboisia plant species scopolamine hyoscine chemically modified quaternary ammonium compound h yoscine butylbromide antispas boehringer ingelheim annual report product portfolio indications brand names active ingredients constipation dulcolax bisacodyl laxative use patients suffering surulac bisacodyl sennoside constipation preparation diagnostic procedures pre post operative treatment conditions require defecation facilitated constipation laxoberal sodium picosulphate laxative use cases constipation laxoberon conditions require defeca guttalax tion facilitated dulcolax np dulcodrops dulcogotas gas bloating dulcogas simethicone fastacting granules relieve gas bloating prevent flatulence abdominal pain buscopan hyoscine butylbromide treatment relief abdominal buscapina cramping pain discomfort heartburn zantac ranitidine relieves heartburn associated acid buscopan antiacido indigestion sour stomach prevents heartburn associated acid indiges tion sour stomach brought certain foods beverages available usa acute diarrhoea vaprino racecadotril treatment symptoms acute diar rhoea adults consumer health care vitamins supplements pharmaton multivitamin mineral supple pharmaton matruelle indicated women ments brand developed support physical men actively planning get pregnant pregnant wom tal wellbeing full range products adapted en breastfeeding women contains important needs different target audiences developed micronutrients mother baby vitamins work harmony body minerals omega fatty acids cover creased needs substances particular pharmaton vitality range products adults periods moreover helps protect embryo contains selected blend vitamins minerals nal neural tube diseases foetus iron trace elements plus standardised ginseng extract folic acid anaemia pregnancy g main target indications exhaustion tiredness decreasing concentration mental alert pharmaton cardioactive product designed ness well cases deficient nutrition loss adults years age contains blend vita appetite debility due illness convalescence mins minerals combined omega fatty acids numerous clinical studies shown regular help maintain cardiovascular health intake pharmaton positive effect mental physical performance wellbeing pharmaton kiddi range products designed children contains selected vitamins minerals essential amino acid lysine important dur ing period growth also recommended preventive treatment vitamin deficiencies boehringer ingelheim annual report product portfolio indications brand names active ingredients tiredness decreasing con pharmaton standardised ginseng improve general wellbeing centration cases defi pharmaton vitality extract vitamins cient nutrition loss appe pharmaton geriavit minerals trace tite debility due illness geriatric pharmaton elements convalescence gericomplex pharmaton complex pharmaton fizzi pharmaton active life increased demand pharmaton kiddi vitamins increased demand vitamins minerals vitamins childhood minerals amino acids especially amino acids period growth preventive treatment cases vitamin deficiencies e g stricted diets convalescence loss appetite following illness infection surgery prophylaxis iron folic pharmaton vitamins minerals women pregnancy acid deficiency matruelle trace elements preventing deficiency symptoms pregnancy omega fatty acids covering increased needs vita docosahexaenoic mins minerals trace elements dha acid dha provide protection embryonal neural tube diseases foetus prophylaxis iron folic acid anae mia pregnancy maintenance pharmaton vitamins minerals trace elements helps maintain cardiovascular health cardio vascular health cardioactive fish oil omega fatty acids rich covers daily needs vitamins pharmaton epa dha minerals trace elements fish oil coractive omega fatty acids rich epa pharmaton protect dha acting complementary daily nutrition consumer health care leg vein health brand name antistax boehringer capsules offer effective treatment described ingel heim markets range products developed symptoms antistax helps keep fluid prevention treatment symptoms attribut flows small venous vessels venules able chronic venous insufficiency com surrounding tissue normal levels even mon symptoms venous insufficiency observable standing sitting long time consumers varicose veins oedema lower leg heavy tired legs sensation tension red vine leaf extract active ingredient tingling cramps pain antistax capsules antistax products antiinflammatory effect tablets scientifically proven help maintain works endothelium inside venules healthy leg vein circulation sealing inside thereby reducing swelling sensation pain heaviness heavy aching tired legs often occur long periods standing sitting increase products available antistax range include end day summer outdoor antistax tablets antistax capsules antistax temperatures rise antistax tablets antistax creme well cosmetic product antistax leg chilling gel urological diseases benign prostate hyperplasia bph refers symptoms luts frequent nighttime enlargement prostate middleaged urination urge urinate every hours weak elderly men lead lower urinary tract flow feeling unfinished urinating boehringer ingelheim annual report product portfolio indications brand names active ingredients chronic venous insufficiency antistax red vine leaf extract prevention treatment symptoms chronic venous insufficiency varicose veins leg oedema painful swollen legs tingling legs tired heavy legs heavy tired legs antistax cooling caring symptomatic treatment heavy tired substances red vine legs leaf extract indications brand names active ingredients benign prostate hyperplasia flomax relief tamsulosin treatment lower urinary tract symp bph toms luts common condition called benign prostate hyperplasia bph available uk animal health foodproducing animals swine infectious respiratory diseases infectious enteric diseases ingelvac circoflex first singledose piglet enterisol ileitis first vaccine vaccine control porcine circovirus disease ileitis caused lawsonia intracellularis licensed pcvd vaccine provides significant reduction improve weight gain reduce growth varia mortality acute phase pcvd well bility associated disease enterisol ileitis improved growth rates chronic phase helps reduce total antimicrobial use pork disease ingelvac circoflex protects minimal production systemic adverse reactions injection site swellings mixing ingelvac circoflex ingelvac mycoflex approved european commis sion ingelvac prrs mlv licensed active im munisation respiratory reproductive form porcine reproductive respiratory syn drome prrs ingelvac mycoflex licensed active immu nisation pigs enzootic pneumonia ep singledose regimen advanced adju vant system provides longlasting effective protection proven even highchallenge situations foodproducing animals poultry volvac umbrella brand boehringer bacterial diseases like avian influenza infectious ingelheim animal health poultry vaccine range bronchitis newcastle disease nfectious bursal dis consists wide range live inactivated vac ease egg drop syndrome avian coryza cines broilers layers vaccines provide volvac vaccines also allow birds express protection birds various viral full potential increase wellbeing boehringer ingelheim annual report product portfolio indications brand names active ingredients infectious respiratory ingelvac circoflex recombinant vaccine active immunisation pigs diseases porcine circovirus age two weeks porcine type pcv circovirus type reduce mortality clinical signs including weight loss lesions lymphoid tissues asso ciated porcine circovirus diseases pcvd addition vaccination shown reduce pcv nasal shedding viral load blood lymphoid tissues duration viraemia infectious respiratory ingelvac prrs mlv attenuated live vaccine active immunisation swine diseases prrs virus age three weeks respiratory reproductive form prrs virus infection porcine reproduc tive respiratory syndrome infectious respiratory ingelvac mycoflex inactivated vaccine active immunisation pigs diseases mycoplasma age three weeks lung hyopneumoniae lesions following infections myco plasma hyopneumoniae infectious enteric diseases enterisol ileitis attenuated live active immunisation pigs vaccine lawsonia age three weeks intestinal intracellularis lesions caused lawsonia intracellula ris infection reduce growth vari ability loss weight gain associat ed disease indications brand names active ingredients various viral bacterial volvac polyvalent attenuated live inac vaccination healthy chickens diseases poultry tivated vaccine containing antigens diseases caused included vaccination avian influ antigens common diseases enza newcastle disease responsible losses egg production avian coryza egg drop layers affecting health syndrome infectious broiler chickens bronchitis infectious bursal disease bacterium anatis animal health foodproducing animals cattle mastitis mastitis inflammation udder dairy cattle mainly caused bacterial infection preven tion treatment mastitis animals key producing healthy milk minimising symptoms associated clinical situation ubrolexin today two products treatment acute bacterial mastitis whereas ubrostar tomorrow used prevent mastitis dryingoff dairy cattle end lactation period mamyzin effective injectable antimicrobial treatment acute mastitis metacam used reduce acute pain associated syndrome boehringer ingelheim annual report product portfolio indications brand names active ingredients mastitis mamyzin penethamate hydroiodide treatment mastitis dairy cows mastitis benestermycin penethamate hydroiodide treatment subclinical mammary ubrostar benethamine penicillin infections present dryingoff framycetin sulphate mastitis ubrolexin cefalexin monohydrate treatment clinical mastitis lactating kanamycin monosulphate dairy cows caused bacteria mastitis today cephapirin sodium intramammary infusion lactat ing cows available usa mastitis tomorrow cephapirin benzathine intramammary infusion dry cow available usa animal health foodproducing animals cattle continued pain inflammatory diseases controls pain supports restoration well metacam member class nonsteroidal farm animals use metacam con antiinflammatory drugs nsaid addresses venient inflicts minimal stress animals due need maintained profitability con lowvolume oneshot dosage cern animal welfare animal production due longacting nature outstanding metacam licensed use cattle suffering efficacy controlling inflammatory symptoms respiratory disease also indicated calves af helps minimise losses inflammation fected diarrhoea adjunctive therapy maintain profitability animals suffering treatment mastitis lactating cows disease time metacam effectively companion animals horse main horse products focus therapeutic laminitis change body conformation lack areas respiratory disease lameness colic performance treatment p rascend life hormonal disorders long ventipulmin treatment acute chronic vetera vaccines first vaccine portfolio respiratory disease airway obstruction due include multiple convenient combinations disease bronchospasm andor mucus accumulation protection horses young four months contributing factor improved mucociliary clear age vaccines protect many nine ance desirable ventipulmin used alone infectious organisms including influenza herpes adjunctive therapy chronic obstructive pul west nile virus tetanus others enables monary disease copd acute subacute customised protection horse limited chronic respiratory allergic conditions needle injections vetera vaccines formulat ed utilising ultrafil purification technology prascend indicated treatment pituitary removing extraneous proteins pars intermedia dysfunction ppid also allowing horses immune system focus known equine cushings disease prascend relevant antigens substitutes lack dopamine pituitary pars intermedia clinical signs hypertrichiosis boehringer ingelheim annual report product portfolio indications brand names active ingredients pain inflammatory metacam meloxicam alleviation inflammation pain diseases muscoloskeletal disorders dog cat pigs horse surgery dog cat pigs colic horse adjunctive treatment diarrhoea respiratory disease acute mastitis dehorning cattle well mastitis metritisagalactia syndrome pigs cattle infectious diseases pyramid attenuated vaccine bovine vaccination healthy dairy beef presponse rhinotracheitisvirus diarrhoea cattle aid prevention diseases parainfluenza respiratory syncytial caused included antigens us virus mannheimia haemolytica canada toxoid indications brand names active ingredients acute chronic obstruc ventipulmin clenbuterol respiratory diseases attended bron tive respiratory diseases chial spasms like subacute chronic bronchitis bronchiolitis chronic obstructive pulmonary disease copd auxillary acute bronchitis pneumonia bronchia pituitary pars intermedia prascend pergolide mesylate treatment clinical signs asso dysfunction ppid ciated pituitary pars intermedia dysfunction ppid also known equine cushings disease way combination vetera eastern western venezuelan vaccination healthy horses vaccines common encephalomyelitis tetanus aid prevention diseases caused diseases horses west nile virus included antigens us canada equine herpes virus equine influenza viruses animal health companion animals small animals main small animal products address major prozinc aqueous protamine zinc pzi sus chronic diseases heart failure kidney disease pension recombinant human insulin used epilepsy osteoarthritis reduce hyperglycaemia cats diabetes mellitus first new class heart treatments termed inodilators vetmedin shown signifi semintra angiotensin ii antagonist cantly improve clinical signs extend life expec newly approved reduction proteinuria associ tancy dogs congestive heart failure origin ated chronic kidney disease ckd cats ating dilated cardiomyopathy valvular semintra decreases mean arterial blood pressure insufficiency mitral andor tricuspid regurgitation proteinuria available oral solution vetmedin works two complementary modes action opens blood vessels taking pexion new alternative treatment ca blood away heart thereby lowering nine epilepsy active substances imepitoin pri pressure heart reducing work marily inhibits seizures via potentiation gabaa heart pump blood around dogs receptormediated inhibitory effects neurons body time vetmedin direct pexion approved reduction generalised effect heart muscle helping beat stronger seizures due idiopathic epilepsy poten pump blood efficiently tial safety benefits existing standard treatment metacam nonsteroidal antiinflammatory drug nsaid available oral suspension tablets injectable solution dogs oral sus pension injectable solution cats dogs indications include alleviation inflammation pain acute chronic musculoskeletal disorders well reduction postoperative pain following surgery cats indications clude alleviation inflammation pain acute chronic musculoskeletal disorders well alleviation mild moderate postoper ative pain following surgical procedures variety formulations offers veterinarians owners flexibility use formulations prefer manage various levels inflammation pain associated licensed indications boehringer ingelheim annual report product portfolio indications brand names active ingredients congestive heart failure vetmedin pimobendan treatment canine congestive heart failure originated dilatative cardio myophathy valvular insufficiency mitral andor tricuspid regurgitation pain inflammatory metacam meloxicam dogs indications include alle diseases viation inflammation pain acute chronic musculoskeletal dis orders well reduction post operative pain following surgery cats indications include alle viation inflammation pain acute chronic musculoskeletal dis orders well alleviation mild moderate postoperative pain follow ing surgical procedures feline diabetes mellitus prozinc protamine zinc reduction hyperglycaemia recombinant hyperglycaemiaassociated clinical signs human insulin cats diabetes mellitus currently available usa feline chronic kidney disease semintra telmisartan reduction proteinuria associated chronic kidney disease ckd cats canine idiopathic epilepsy pexion imepitoin reduction frequency generalised seizures due idiopathic epilepsy dogs careful evaluation alternative treatment options c h boehringer sohn ag co kg ingelheim comparison balance sheets financial data comparison balance sheets millions eur assets december intangible assets tangible assets financial assets fixed assets inventories accounts receivable incl deferred charges deferred taxes liquid funds current assets incl deffered charges deferred taxes total assets liabilities equity december shareholders capital reserves incl currency conversion difference net income total equity minority interests group equity negative difference acquisition companies provisions incl deferred taxes liabilities incl deferred charges total liabilities incl deferred taxes deferred charges total liabilities equity summary selected financial data net sales operating income operating income net sales income taxes income taxes net sales return shareholders equity equity ratio cash flow financial funds personnel costs personnel costs net sales average number employees research development costs r net sales investments tangible assets depreciation tangible assets comparison balance sheets millions eur assets december intangible assets tangible assets financial assets fixed assets inventories accounts receivable incl deferred charges deferred taxes liquid funds current assets incl deffered charges deferred taxes total assets liabilities equity december shareholders capital reserves incl currency conversion difference net income total equity minority interests group equity negative difference acquisition companies provisions incl deferred taxes liabilities incl deferred charges total liabilities incl deferred taxes deferred charges total liabilities equity summary selected financial data net sales operating income operating income net sales income taxes income taxes net sales return shareholders equity equity ratio cash flow financial funds personnel costs personnel costs net sales average number employees research development costs r net sales investments tangible assets depreciation tangible assets queries comments please contact us boehringer ingelheim gmbh binger strasse ingelheim germany telephone fax contact corporate division communications email webmasterboehringeringelheimcom internet wwwboehringeringelheimcom issued boehringer ingelheim gmbh concept design layout mpm gmbh corporate communication solutions wwwdigitalagenturmpmde photos lukas beck p james horan p lorenzo vannucci p printed sddeutsche verlagsgesellschaft ulm copyright boehringer ingelheim gmbh rights reserved part annual report may reproduced transmitted form means electronic photocopy without permission writing boehringer ingelheim gmbh figures third parties used annual report based data available time financial statement drawn upwwwboehringeringelheimcom annualreportboehringeringelheimcom